<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Levofloxacin (systemic): Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Levofloxacin (systemic): Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Levofloxacin (systemic): Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="10214" href="/d/html/10214.html" rel="external">see "Levofloxacin (systemic): Drug information"</a> and <a class="drug drug_patient" data-topicid="12239" href="/d/html/12239.html" rel="external">see "Levofloxacin (systemic): Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F8398365"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Serious adverse reactions:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Fluoroquinolones have been associated with disabling and potentially irreversible serious adverse reactions that have occurred together, including tendinitis and tendon rupture, peripheral neuropathy, and CNS effects. Discontinue levofloxacin immediately and avoid the use of fluoroquinolones in patients who experience any of these serious adverse reactions. Because fluoroquinolones have been associated with serious adverse reactions, reserve levofloxacin for use in patients who have no alternative treatment options for the following indications: uncomplicated urinary tract infection, acute bacterial exacerbation of chronic bronchitis, and acute bacterial sinusitis.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Exacerbation of myasthenia gravis:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Fluoroquinolones may exacerbate muscle weakness in patients with myasthenia gravis. Avoid levofloxacin in patients with a known history of myasthenia gravis.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F8398376"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Levaquin [DSC]</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52869222"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>ACT Levofloxacin;</li>
<li>APO-Levofloxacin;</li>
<li>JAMP-Levofloxacin;</li>
<li>MINT-Levofloxacin;</li>
<li>RIVA-Levofloxacin;</li>
<li>SANDOZ Levofloxacin</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F10501846"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antibiotic, Quinolone</span></li></ul></div>
<div class="block dop drugH1Div" id="F8406521"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosage form information:</b> Concentration of oral suspension may vary (commercially available or extemporaneous compounded); use caution.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Clinical considerations</b>: In pediatric patients, fluoroquinolones are not routinely first-line therapy, but after assessment of risks and benefits, can be considered a reasonable alternative for situations where no safe and effective substitute is available (eg, multidrug resistance) or in situations where the only alternative is parenteral therapy and levofloxacin offers an oral therapy option (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27940800']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27940800'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>General dosing, susceptible infection</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27940800']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27940800'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:4em;">Infants ≥6 months, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">6 months to &lt;5 years: Oral, IV: 8 to 10 mg/kg/dose twice daily.</p>
<p style="text-indent:-2em;margin-left:6em;">≥5 years: Oral, IV: 10 mg/kg/dose once daily; maximum dose: 750 mg/<b>day</b>.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c74e9b7c-3d24-4a43-8fa5-6da3c93d72db">Anthrax</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Anthrax: </b>Limited data available in infants &lt;6 months of age: <b>Note:</b> Levofloxacin is not preferred therapy for any prophylaxis or treatment regimens; use should be considered when patients are unable to tolerate first-line therapy (eg, ciprofloxacin or others depending upon disease presentation). Although longer durations of therapy are recommended in guidelines in some cases based on risk:benefit assessments (eg, up to 60 days), specific safety data for levofloxacin in pediatric patients is limited to 14 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24777226']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24777226'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Cutaneous, without systemic involvement; treatment</i> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24777226']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24777226'])">Ref</a></span>): Appropriate for all strains regardless of penicillin susceptibility or if susceptibility unknown. Treatment duration: 7 to 10 days for naturally-acquired infection, and up to 60 days for biological weapon-related event.</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>&lt;</i>50 kg: Oral: 8 mg/kg/dose every 12 hours; maximum dose: 250 mg/dose.</p>
<p style="text-indent:-2em;margin-left:8em;">≥50 kg: Oral: 500 mg every 24 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Inhalational (postexposure prophylaxis)</i> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24777226']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24777226'])">Ref</a></span>): Reserve levofloxacin use for penicillin-resistant strains or prior to susceptibility testing. Begin therapy as soon as possible after exposure.</p>
<p style="text-indent:-2em;margin-left:8em;">&lt;50 kg: Oral (preferred), IV: 8 mg/kg/dose every 12 hours for 60 days; maximum dose: 250 mg/dose.</p>
<p style="text-indent:-2em;margin-left:8em;">≥50 kg: Oral (preferred), IV: 500 mg every 24 hours for 60 days.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Systemic anthrax (excluding meningitis); treatment</i> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24777226']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24777226'])">Ref</a></span>): <b>Note:</b> A fluoroquinolone is appropriate for all strains regardless of penicillin susceptibility or if susceptibility unknown; ciprofloxacin is preferred.</p>
<p style="text-indent:-2em;margin-left:8em;">Initial treatment: Use in combination with a protein synthesis inhibitor (eg, clindamycin); continue therapy for at least 14 days or longer until clinical criteria for stability are met.</p>
<p style="text-indent:-2em;margin-left:10em;">&lt;50 kg: IV: 10 mg/kg/dose every 12 hours; maximum dose: 250 mg/dose.</p>
<p style="text-indent:-2em;margin-left:10em;">≥50 kg: IV: 500 mg every 24 hours.</p>
<p style="text-indent:-2em;margin-left:8em;">Oral step-down therapy: Use in combination with a protein synthesis inhibitor (eg, clindamycin). Duration of therapy to complete treatment course is variable; some patients may require up to 60 days additional prophylaxis from onset of illness.</p>
<p style="text-indent:-2em;margin-left:10em;">&lt;50 kg: Oral: 8 mg/kg/dose every 12 hours; maximum dose: 250 mg/dose.</p>
<p style="text-indent:-2em;margin-left:10em;">≥50 kg: Oral: 500 mg every 24 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>
<i>Systemic anthrax; disseminated infection including meningitis (or when meningitis cannot be ruled out): </i></i></p>
<p style="text-indent:-2em;margin-left:8em;">Initial triple therapy: Use in combination with another bactericidal antimicrobial (beta-lactam or glycopeptide [depending on susceptibility]) and a protein synthesis inhibitor (eg, linezolid); continue therapy for at least 2 to 3 weeks or longer until clinical criteria for stability are met.</p>
<p style="text-indent:-2em;margin-left:10em;">&lt;50 kg: IV: 8 mg/kg/dose every 12 hours; maximum dose: 250 mg/dose.</p>
<p style="text-indent:-2em;margin-left:10em;">≥50 kg: IV: 500 mg every 24 hours.</p>
<p style="text-indent:-2em;margin-left:8em;">Oral step-down therapy: Use in combination with a protein synthesis inhibitor (eg, clindamycin). Duration of therapy to complete treatment course is variable; some patients may require up to 60 days additional prophylaxis from onset of illness.</p>
<p style="text-indent:-2em;margin-left:10em;">&lt;50 kg: Oral: 8 mg/kg/dose every 12 hours; maximum dose: 250 mg/dose.</p>
<p style="text-indent:-2em;margin-left:10em;">≥50 kg: Oral: 500 mg every 24 hour.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="dc12195f-0fc0-4f5b-813b-2edc30aa1d45">Bacteremia prophylaxis in patients with acute myeloid leukemia or relapsed acute lymphocytic leukemia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Bacteremia prophylaxis in patients with acute myeloid leukemia (AML) or relapsed acute lymphocytic leukemia (ALL): Note:</b> Recommended only during period when patient is severely neutropenic (ie, when absolute neutrophil count [ANC] is &lt;500 cells/mm<sup>3</sup>) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31676904']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31676904'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants ≥6 months and Children &lt;5 years: Oral, IV: 10 mg/kg/dose every 12 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30208456']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30208456'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥5 years and Adolescents: Oral, IV: 10 mg/kg/dose every 24 hours; maximum dose: 750 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30208456']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30208456'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4150df16-0a9a-4d2c-9319-ed75050f5b4b">Chlamydia trachomatis, urogenital infections</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Chlamydia trachomatis, </i>urogenital infections: </b>Adolescents: Oral: 500 mg every 24 hours for 7 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26042815']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26042815'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="7005ad11-2732-4b54-b717-9f378f48caf1">Cystic fibrosis pulmonary exacerbation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cystic fibrosis pulmonary exacerbation:</b> Limited data available (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25102221']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25102221'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:4em;">Infants ≥6 months, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">6 months to &lt;5 years: Oral, IV: 10 mg/kg/dose twice daily.</p>
<p style="text-indent:-2em;margin-left:6em;">≥5 years: Oral, IV: 10 mg/kg/dose once daily; maximum dose: 750 mg/<b>day</b>.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e1ae449e-22c1-405a-94bf-7e5c40bdc029">Epididymitis, nongonococcal</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Epididymitis, nongonococcal:</b> Adolescents: Oral: 500 mg once daily for 10 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26042815']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26042815'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9938d465-584f-48f7-8083-e90bc984c47e">Exit-site or tunnel infection, peritoneal dialysis catheter</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Exit-site or tunnel infection, peritoneal dialysis catheter:</b> Infants, Children, and Adolescents: Oral: 10 mg/kg/dose every 48 hours; maximum initial dose: 500 mg; maximum subsequent doses: 250 mg (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22851742']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22851742'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="6adb8e15-e2f2-47a7-b838-381048e95138">Mycobacterium avium Complex, severe or disseminated disease, HIV-exposed/-infected</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Mycobacterium avium Complex</i></b>
<b>, severe or disseminated disease, HIV-exposed/-infected</b>: Adolescents: Oral: 500 mg once daily in combination with other antibiotics (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.2016']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.2016'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a96b8104-65d0-48ba-b460-4308464e6db6">Otitis media, acute</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Otitis media, acute (AOM) (alternative agent): </b>Limited data available: <b>Note: </b>Not recommended for routine empiric use; may be considered for patients with severe penicillin allergy, persistent or recurrent infection, or resistant causative bacteria (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27940800','lexi-content-ref-23439909','lexi-content-ref-Bradley.1','lexi-content-ref-18449063']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27940800','lexi-content-ref-23439909','lexi-content-ref-Bradley.1','lexi-content-ref-18449063'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants ≥6 months and Children &lt;5 years: Oral: 10 mg/kg/dose every 12 hours for 10 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17133154','lexi-content-ref-18449063']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17133154','lexi-content-ref-18449063'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥5 years and Adolescents: Oral: 10 mg/kg/dose every 24 hours for 10 days; maximum dose: 750 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27940800','lexi-content-ref-23439909','lexi-content-ref-Bradley.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27940800','lexi-content-ref-23439909','lexi-content-ref-Bradley.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="19ad33d2-38a3-4047-a6e2-816347270335">Pelvic inflammatory disease</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pelvic inflammatory disease:</b> Adolescents: Oral: 500 mg once daily for 14 days with or without concomitant metronidazole; <b>Note:</b> Due to resistant organisms, the CDC recommends use as an alternative therapy only if standard parenteral cephalosporin therapy is not feasible and community prevalence, and individual risk of quinolone-resistant gonococcal organisms is low. Culture sensitivity must be confirmed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26042815']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26042815'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f38f48ce-bca2-4bb4-a7be-efee962597ea">Plague, prophylaxis or treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Plague <i>(Yersinia pestis)</i>, prophylaxis or treatment:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Infants ≥6 months, Children, and Adolescents: <b>Note:</b> Begin therapy as soon as possible after exposure:</p>
<p style="text-indent:-2em;margin-left:6em;">&lt;50 kg: Oral, IV: 8 mg/kg/dose every 12 hours for 10 to 14 days; maximum dose: 250 mg/dose.</p>
<p style="text-indent:-2em;margin-left:6em;">≥50 kg: Oral, IV: 500 mg every 24 hours for 10 to 14 days.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ed599b2f-52de-47cd-b7d2-d706008b1db0">Pneumonia, community-acquired</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pneumonia, community-acquired (CAP)</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21880587']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21880587'])">Ref</a></span>): <b>Note:</b> May consider addition of vancomycin or clindamycin to empiric therapy if community-acquired MRSA suspected. Levofloxacin is not the preferred agent for CAP but may be used as an alternative agent when necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Typical pathogens (eg, H. influenzae, S. pneumoniae): </i>
<b>Note:</b> Oral administration is generally reserved for mild infections or step-down therapy.</p>
<p style="text-indent:-2em;margin-left:6em;">Infants ≥6 months and Children &lt;5 years: Oral, IV: 8 to 10 mg/kg/dose every 12 hours; maximum daily dose: 750 mg/<b>day</b>.</p>
<p style="text-indent:-2em;margin-left:6em;">Children ≥5 years and Adolescents ≤16 years: Oral, IV: 8 to 10 mg/kg/dose once every 24 hours; maximum daily dose: 750 mg/<b>day</b>.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Atypical pathogens (eg, <i>Mycoplasma pneumonia</i> or <i>Chlamydia ssp</i>):</i></p>
<p style="text-indent:-2em;margin-left:6em;">IV:</p>
<p style="text-indent:-2em;margin-left:8em;">Infants ≥6 months and Children &lt;5 years: IV: 8 to 10 mg/kg/dose every 12 hours; maximum daily dose: 750 mg/<b>day</b>.</p>
<p style="text-indent:-2em;margin-left:8em;">Children ≥5 years and Adolescents ≤16 years: IV: 8 to 10 mg/kg/dose once every 24 hours; maximum daily dose: 750 mg/<b>day</b>.</p>
<p style="text-indent:-2em;margin-left:6em;">Oral: Mild infection/step-down therapy: Adolescents with skeletal maturity: Oral: 500 mg once daily.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1437b55a-5145-4c15-bba4-c28709c37109">Rhinosinusitis, acute bacterial</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Rhinosinusitis, acute bacterial: Note:</b> Recommended in the following types of patients: Type I penicillin allergy, after failure of initial therapy or in patients at risk for antibiotic resistance (eg, daycare attendance, age &lt;2 years, recent hospitalization, antibiotic use within the past month) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22438350']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22438350'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Children and Adolescents: Oral, IV: 10 to 20 mg/kg/<b>day</b> divided every 12 to 24 hours for 10 to 14 days; maximum daily dose: 500 mg/<b>day</b>.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="fa7b6aef-11c5-4b72-97a0-a39f0f808184">Surgical prophylaxis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Surgical prophylaxis:</b> Children and Adolescents: IV: 10 mg/kg as a single dose 120 minutes prior to procedure; maximum dose: 500 mg/dose; <b>Note:</b> While fluoroquinolones have been associated with an increased risk of tendinopathy/tendon rupture in all ages, use of these agents for single-dose prophylaxis is generally safe (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23461695']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23461695'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="89056b8d-2a19-4dda-aba2-d1fe9dbecb64">Tuberculosis, multidrug-resistant</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Tuberculosis (TB), multidrug-resistant:</b> Limited data available: <b>Note:</b> Use in combination with at least 3 to 4 additional anti-TB agents (overall multidrug regimen dependent upon susceptibility profile/patterns) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31729908','lexi-content-ref-AAP.1','lexi-content-ref-WHO.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31729908','lexi-content-ref-AAP.1','lexi-content-ref-WHO.2019'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents: Oral: 15 to 20 mg/kg/dose once daily; usual maximum daily dose: 1,000 mg/<b>day</b>; higher doses (1,250 to 1,500 mg/<b>day</b>) have been reported in adults (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31729908','lexi-content-ref-AAP.1','lexi-content-ref-WHO.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31729908','lexi-content-ref-AAP.1','lexi-content-ref-WHO.2019'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3fd26f11-1af1-4e70-b617-c8cbe0250c68">Urethritis, nongonococcal</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Urethritis, nongonococcal:</b> Adolescents: Oral: 500 mg every 24 hours for 7 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26042815']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26042815'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51117769"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Infants, Children, and Adolescents: IV, Oral: The following adjustments have been recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Aronoff.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Aronoff.1'])">Ref</a></span>). <b>Note:</b> Renally adjusted dose recommendations are based on doses of 5 to 10 mg/kg/dose every 12 hours in ages ≤5 years and 5 to 10 mg/kg/dose every 24 hours in ages &gt;5 years.</p>
<p style="text-indent:-2em;margin-left:4em;">GFR ≥30 mL/minute/1.73 m<sup>2</sup>: No adjustment necessary</p>
<p style="text-indent:-2em;margin-left:4em;">GFR 10 to 29 mL/minute/1.73 m<sup>2</sup>: 5 to 10 mg/kg/dose every 24 hours</p>
<p style="text-indent:-2em;margin-left:4em;">GFR &lt;10 mL/minute/1.73 m<sup>2</sup>: 5 to 10 mg/kg/dose every 48 hours</p>
<p style="text-indent:-2em;margin-left:4em;">Intermittent hemodialysis: 5 to 10 mg/kg/dose every 48 hours; not removed by hemodialysis; supplemental levofloxacin doses are not required</p>
<p style="text-indent:-2em;margin-left:4em;">Peritoneal dialysis (PD): 5 to 10 mg/kg/dose every 48 hours; not removed by peritoneal dialysis; supplemental levofloxacin doses are not required</p>
<p style="text-indent:-2em;margin-left:4em;">Continuous renal replacement therapy (CRRT): 10 mg/kg/dose every 24 hours</p></div>
<div class="block dohp drugH1Div" id="F51117770"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; has not been studied; however, dosage adjustment unlikely to be necessary due to limited hepatic metabolism.</p></div>
<div class="block doa drugH1Div" id="F8406522"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="10214" href="/d/html/10214.html" rel="external">see "Levofloxacin (systemic): Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c74e9b7c-3d24-4a43-8fa5-6da3c93d72db">Anthrax</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Anthrax:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Consult public health officials for event-specific recommendations.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>
<b>Inhalational (postexposure prophylaxis) (alternative agent)</b></i>
<b>: </b>
<b>Oral:</b> 750 mg every 24 hours; duration depends on anthrax vaccine status and series completion, age, immune status, and pregnancy/breastfeeding status. For those who have not previously received an anthrax vaccine, duration ranges from 42 to 60 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31834290']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31834290'])">Ref</a></span>). Some experts favor longer durations of prophylaxis (eg, total of 3 to 4 months) for patients who are immunocompromised or remain unvaccinated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Wilson.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Wilson.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> Anthrax vaccine should also be administered to exposed individuals (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31834290','lexi-content-ref-24447897']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31834290','lexi-content-ref-24447897'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>
<b>Cutaneous (without systemic involvement), treatment (off-label use)</b></i>
<b>: </b>
<b>Oral:</b> 750 mg every 24 hours for 7 to 10 days after naturally acquired infection; treat for 60 days for bioterrorism-related cases. <b>Note:</b> Treat patients with extensive edema or cutaneous lesions of the head or neck with a parenteral regimen recommended for systemic involvement (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24447897']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24447897'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Systemic (with or without meningitis), treatment (alternative agent) (off-label use)</i>: IV:</b> 750 mg every 24 hours, in combination with other appropriate agents for ≥2 to 3 weeks or until clinically stable, whichever is longer (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24447897']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24447897'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Antitoxin should also be administered for patients with suspected systemic anthrax. Following the course of IV combination therapy for systemic anthrax infection (including meningitis), patients exposed to aerosolized spores require oral monotherapy to complete a total antimicrobial course of 60 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24447897']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24447897'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="bb1f0aaf-41ff-4651-ad53-d81e2f072c7d">Bite wound infection, prophylaxis or treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Bite wound infection, prophylaxis or treatment (animal or human bite) (alternative agent) (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral, IV:</b> 750 mg once daily, in combination with an agent appropriate for anaerobes. Duration of therapy is 3 to 5 days for prophylaxis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24947530']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24947530'])">Ref</a></span>); duration of treatment for established infection is typically 5 to 14 days and varies based on patient-specific factors, including clinical response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Baddour.1','lexi-content-ref-Baddour.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Baddour.1','lexi-content-ref-Baddour.2'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="bbd52e21-dcfe-472c-a480-3587971723ab">Chronic obstructive pulmonary disease, acute exacerbation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Chronic obstructive pulmonary disease, acute exacerbation: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Some experts reserve for outpatients with risk factors for poor outcomes (eg, ≥65 years of age, FEV<sub>1</sub> &lt;50% predicted, frequent exacerbations, significant comorbidities) or for inpatients without risk factors for <i>Pseudomonas</i> infection (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Sethi.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Sethi.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral, IV:</b> 500 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12628877']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12628877'])">Ref</a></span>) for 5 to 7 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-GOLD.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-GOLD.1'])">Ref</a></span>); use 750 mg once daily if <i>P. aeruginosa </i>is suspected (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15929954','lexi-content-ref-22210007']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15929954','lexi-content-ref-22210007'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c82d3ece-50d0-49c2-ae32-3a2c16f1d66e">Diabetic foot infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Diabetic foot infection (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>When used as empiric therapy, levofloxacin should be used in combination with other appropriate agents.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mild to moderate infection</i>: <b>Oral:</b> 500 mg every 24 hours (750 mg every 24 hours if <i>P. aeruginosa</i> is suspected) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22619242','lexi-content-ref-Weintrob.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22619242','lexi-content-ref-Weintrob.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Moderate to severe infection (alternative agent)</i>: <b>IV:</b> 750 mg every 24 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22619242','lexi-content-ref-Weintrob.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22619242','lexi-content-ref-Weintrob.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8b8d4809-3f39-4624-a159-df262570daf3">
<i>Helicobacter pylori</i> eradication</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Helicobacter pylori</b></i>
<b>eradication (salvage regimen) (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Reserve use for levofloxacin susceptible isolates or if the population resistance rate is &lt;15% (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33524402']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33524402'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Levofloxacin triple regimen: <b>Oral:</b> Levofloxacin 500 mg once daily, in combination with amoxicillin 750 mg 3 times daily, plus a double-dose proton pump inhibitor twice daily; continue regimen for 14 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33524402']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33524402'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c9474c76-c81a-48ef-b80f-72ce1a0e25f5">Intra-abdominal infection, mild to moderate, community-acquired in patients without risk factors for resistance or treatment failure</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Intra-abdominal infection, mild to moderate, community-acquired in patients without risk factors for resistance or treatment failure (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Empiric oral regimens may be appropriate for patients with mild to moderate infection. Other patients may be switched from IV to oral therapy when clinically improved and able to tolerate an oral diet (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28085573','lexi-content-ref-20034345']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28085573','lexi-content-ref-20034345'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Cholecystitis, acute:</i>
<b>IV, Oral:</b> 750 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20034345']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20034345'])">Ref</a></span>); continue for 1 day after gallbladder removal or until clinical resolution in patients managed nonoperatively (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28085573','lexi-content-ref-20034345','lexi-content-ref-Vollmer.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28085573','lexi-content-ref-20034345','lexi-content-ref-Vollmer.1'])">Ref</a></span>). <b>Note: </b>The addition of anaerobic therapy (eg, metronidazole) is recommended if biliary-enteric anastomosis is present (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20034345']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20034345'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Other intra-abdominal infections (eg, perforated appendix, diverticulitis, intra-abdominal abscess): </i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> For acute diverticulitis, some experts suggest deferring antibiotics in otherwise healthy patients who are immunocompetent with mild disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26453777','lexi-content-ref-30664553','lexi-content-ref-34183510','lexi-content-ref-28719679','lexi-content-ref-28085573','lexi-content-ref-32073652']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26453777','lexi-content-ref-30664553','lexi-content-ref-34183510','lexi-content-ref-28719679','lexi-content-ref-28085573','lexi-content-ref-32073652'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV, Oral:</b> 750 mg once daily in combination with metronidazole. Total duration of therapy (which may include transition to oral antibiotics) is 4 to 5 days following adequate source control (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25992746','lexi-content-ref-28085573']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25992746','lexi-content-ref-28085573'])">Ref</a></span>). For diverticulitis or uncomplicated appendicitis managed without intervention, duration is 10 to 14 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Barshak.1','lexi-content-ref-Pemberton.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Barshak.1','lexi-content-ref-Pemberton.1'])">Ref</a></span>); for perforated appendicitis managed with laparoscopic appendectomy, 2 to 4 days may be sufficient (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36669519','lexi-content-ref-25992746']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36669519','lexi-content-ref-25992746'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="386921fa-07a3-493e-a6cb-8d72fb9ffb37">Neutropenia, antibacterial prophylaxis in high-risk patients anticipated to have an ANC ≤100 cells/mm<sup>3</sup> for &gt;7 days</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Neutropenia (chemotherapy-induced), antibacterial prophylaxis in high-risk patients anticipated to have an ANC ≤100 cells/mm<sup>3</sup> for &gt;7 days (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 500 or 750 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16148283','lexi-content-ref-16148284','lexi-content-ref-21258094','lexi-content-ref-29170868','lexi-content-ref-Wingard.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16148283','lexi-content-ref-16148284','lexi-content-ref-21258094','lexi-content-ref-29170868','lexi-content-ref-Wingard.1'])">Ref</a></span>). Some clinicians will provide antibacterial prophylaxis if ANC is anticipated to be &lt;500 cells/mm<sup>3</sup> for &gt;7 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Wingard.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Wingard.1'])">Ref</a></span>). For hematopoietic cell transplant recipients, begin at the time of stem cell infusion and continue until recovery of neutropenia or until initiation of empiric antibiotic therapy for neutropenic fever (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19747629']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19747629'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d31b3c05-03cb-4fcd-8932-e9d1953c0ab8">Odontogenic soft tissue infection, pyogenic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Odontogenic soft tissue infection, pyogenic (alternative agent) (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>For patients unable to take beta-lactams (Chow 2022).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV, Oral:</b> 750 mg once daily in combination with metronidazole; continue until clinical resolution, typically for 7 to 14 days. Use in addition to appropriate surgical management (eg, drainage and/or extraction) (Chow 2022).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a9d9ff41-d96a-4eb8-b9f5-e76594705fc3">Osteomyelitis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Osteomyelitis (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral, IV:</b> 750 mg once daily for ≥6 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26316526','lexi-content-ref-Osmon.2019','lexi-content-ref-18230552']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26316526','lexi-content-ref-Osmon.2019','lexi-content-ref-18230552'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="2d4cf660-fc6c-4182-9e8b-10ee80fcb30b">Plague</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Plague (<i>Yersinia pestis</i>): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Consult public health officials for event-specific recommendations:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Treatment</i>: <b>Oral, IV:</b> 750 mg every 24 hours for 7 to 14 days and for at least a few days after clinical resolution (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34264565','lexi-content-ref-Stout.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34264565','lexi-content-ref-Stout.1'])">Ref</a></span>). For plague meningitis, use as part of an appropriate combination regimen (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34264565']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34264565'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Postexposure prophylaxis</i>: <b>Oral:</b> 500 to 750 mg once daily for 7 days; use 750 mg once daily in patients who are pregnant (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34264565']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34264565'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="7792e77c-7758-4230-a81e-dc7dd3a6acb9">Pneumonia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pneumonia:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Community-acquired pneumonia</i>:</b> Outpatients with comorbidities or inpatients:</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> Some experts reserve fluoroquinolones for patients who cannot take other preferred regimens (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-File.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-File.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral, IV:</b> 750 mg once daily. For inpatients with severe pneumonia or risk factors for methicillin-resistant <i>Staphylococcus aureus</i>, use as part of an appropriate combination regimen. Duration is for a minimum of 5 days; a longer course may be required for patients with an immunocompromising condition, severe or complicated infection, or for <i>P. aeruginosa</i> infection. Patients should be clinically stable with normal vital signs prior to discontinuation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31573350','lexi-content-ref-32561442']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31573350','lexi-content-ref-32561442'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>
<b>Hospital-acquired or ventilator-associated pneumonia</b></i>
<b>:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> For empiric therapy, use in combination with other appropriate agents (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27418577']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27418577'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral, IV:</b> 750 mg every 24 hours. Duration of therapy varies based on disease severity and response to therapy; treatment is typically given for 7 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27418577']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27418577'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1fd32e36-aea8-4922-9fc3-8f98fc89d1d8">Prostatitis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Prostatitis:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>
<b>Acute bacterial prostatitis (off-label use)</b></i>
<b>:</b>
<b>Oral, IV:</b> 500 mg once daily for 4 to 6 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Meyrier.2022a']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Meyrier.2022a'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>
<b>Chronic bacterial prostatitis</b></i>
<b>:</b>
<b>Oral:</b> 500 mg once daily for 4 to 6 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Meyrier.2021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Meyrier.2021'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9d1b4c51-5035-4766-b50d-dd4e58990353">Prosthetic joint infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Prosthetic joint infection (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Treatment:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Gram-negative bacilli: <b>Oral, IV:</b> 750 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Berbari.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Berbari.2019'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Staphylococcus aureus</i>, oral continuation therapy (following pathogen-specific IV therapy in patients undergoing 1-stage exchange or debridement with retention of prosthesis): <b>Oral:</b> 500 to 750 mg once daily in combination with rifampin; duration is a minimum of 3 months, depending on patient-specific factors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Berbari.2019','lexi-content-ref-23223583']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Berbari.2019','lexi-content-ref-23223583'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Chronic suppressive therapy for gram-negative bacilli</i>: <b>Oral:</b> 500 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Berbari.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Berbari.2019'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1437b55a-5145-4c15-bba4-c28709c37109">Rhinosinusitis, acute bacterial</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Rhinosinusitis, acute bacterial (alternative agent):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> In uncomplicated acute bacterial rhinosinusitis, initial observation and symptom management without antibiotic therapy is appropriate in most patients. Reserve antibiotic therapy for poor follow-up or lack of improvement over the observation period (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25832968','lexi-content-ref-26785402']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25832968','lexi-content-ref-26785402'])">Ref</a></span>). Due to risks associated with use, reserve fluoroquinolones for those who have no alternative treatment options (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-FDA..2016']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-FDA..2016'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 500 mg or 750 mg once daily for 5 to 7 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22438350','lexi-content-ref-Patel.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22438350','lexi-content-ref-Patel.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8c766fcd-fae9-4e93-a37a-c8c768efd0df">
<i>Salmonella</i> infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Salmonella</b></i>
<b> (nontyphoidal) infection (alternative agent):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>
<b>GI infection: </b></i>Oral, IV: 500 mg once daily for 3 to 14 days (7 to 14 days in patients with HIV with a CD4 count ≥200 cells/mm<sup>3</sup>). Immunosuppressed patients (eg, patients with HIV and CD4 count &lt;200 cells/mm<sup>3</sup>) require longer duration of treatment (eg, weeks to months) and may require a higher dose (eg, 750 mg once daily). <b>Note:</b> Reserve antibiotic treatment for patients with severe illness or at high risk of invasive disease (eg, extremes of age, immunosuppression); reserve parenteral therapy for those who cannot tolerate oral agents (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.2020','lexi-content-ref-Hohmann.2020a']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.2020','lexi-content-ref-Hohmann.2020a'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>
<b>Bacteremia:</b></i> Oral, IV: 500 or 750 mg once daily for 14 days. <b>Note:</b> Immunosuppressed patients (eg, HIV-infected with CD4 count &lt;200 cells/mm<sup>3</sup>) and those with an extraintestinal focus of infection warrant a longer duration of treatment (eg, weeks to months) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.2020','lexi-content-ref-Hohmann.2020b']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.2020','lexi-content-ref-Hohmann.2020b'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8597b7bf-d38b-46ed-ae30-27103563bc5c">Sexually transmitted infections</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Sexually transmitted infections:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Cervicitis/urethritis due to Chlamydia trachomatis (alternative agent) (off-label use)</i>:</b>
<b>Oral:</b> 500 mg once daily for 7 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34292926']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34292926'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Epididymitis, acute (off-label use):</i></b></p>
<p style="text-indent:-2em;margin-left:6em;">Patients ≥35 years of age <b>and</b> who are at low risk for sexually transmitted diseases (ie, likely caused by enteric organisms): <b>Oral:</b> 500 mg once daily for 10 days. <b>Note:</b> In patients &lt;35 years of age or who are at risk of sexually transmitted diseases, fluoroquinolones are not recommended due to widespread resistance of <i>N. gonorrhoeae </i>to these agents (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34292926','lexi-content-ref-Eyre.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34292926','lexi-content-ref-Eyre.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Males of any age who practice insertive anal sex (ie, likely caused by sexually transmitted <i>Chlamydia trachomatis</i> or <i>N. gonorrhoeae</i>, and enteric organisms): <b>Oral:</b> 500 mg once daily for 10 days, in combination with a single dose of ceftriaxone (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34292926','lexi-content-ref-Eyre.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34292926','lexi-content-ref-Eyre.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>
<b>Pelvic inflammatory disease, outpatient therapy, mild to moderate disease (alternative agent) (off-label use)</b></i>
<b>:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> Reserve for patients who cannot use first-line options and are at low risk for fluoroquinolone-resistant <i>N. gonorrhoeae</i> (eg, prevalence is &lt;5% in the location where the infection was acquired) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34292926','lexi-content-ref-Wiesenfeld.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34292926','lexi-content-ref-Wiesenfeld.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b> 500 mg once daily in combination with metronidazole for 14 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34292926']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34292926'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="dc511cf9-80be-4243-a139-df398f0bd937">
<i>Shigella</i> GI infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Shigella</i> GI infection (alternative agent) (off-label use): </b>
<b>Note: </b>Use only if ciprofloxacin MIC is &lt;0.12 mcg/mL (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.2020','lexi-content-ref-29053792']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.2020','lexi-content-ref-29053792'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 500 or 750 mg once daily for 3 days; the duration should be extended to 5 to 7 days for those with <i>S. dysenteriae</i> type 1 infection or HIV coinfection (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Agha.2020','lexi-content-ref-HHS.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Agha.2020','lexi-content-ref-HHS.2020'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5fe294fd-4626-4e48-9579-84675accedc8">Skin and soft tissue infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Skin and soft tissue infection:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>
<b>Cellulitis or abscess (alternative agent):</b></i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> Reserve for patients who require broad spectrum therapy because of severe sepsis or immunocompromising condition who cannot take beta-lactams (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24947530','lexi-content-ref-Spelman.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24947530','lexi-content-ref-Spelman.1'])">Ref</a></span>). For patients with severe sepsis, initial therapy with IV is recommended with transition to oral therapy when clinical improvement and sepsis resolution occurs (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Spelman.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Spelman.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral, IV:</b> 750 mg once daily in combination with other appropriate agents. Treat for 5 to 14 days depending on severity and clinical response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24947530','lexi-content-ref-Spelman.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24947530','lexi-content-ref-Spelman.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>
<b>Surgical site incisional infection:</b></i></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Intestinal or genitourinary tract surgery:</i>
<b>IV:</b> 750 mg every 24 hours in combination with metronidazole (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24947530']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24947530'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Perineum or axilla surgery:</i>
<b>Oral, IV:</b> 750 mg every 24 hours in combination with metronidazole (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24947530']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24947530'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="81f18aee-603f-4947-a2fa-46af87fa186f">
<i>S. maltophilia</i> infection, multidrug-resistant</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:0em;">
<b>
<i>S. maltophilia</i> infection, multidrug-resistant (alternative agent) (off-label use): Oral, IV: </b>750 mg every 24 hours. For mild infection, may use as monotherapy; however, use with caution, as resistance may develop during therapy. For moderate to severe infection, administer as part of an appropriate combination regimen (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34864936']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34864936'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="fa7b6aef-11c5-4b72-97a0-a39f0f808184">Surgical prophylaxis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Surgical (preoperative) prophylaxis (alternative agent) (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 500 mg beginning 120 minutes prior to initial surgical incision; use in combination with other appropriate agents may be warranted (procedure dependent) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23327981']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23327981'])">Ref</a></span>). <b>Note: </b>Postoperative prophylaxis is not recommended for clean and clean-contaminated surgeries (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28467526']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28467526'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a332cb4b-40bc-4f93-9a74-b665db48cb3b">Tuberculosis, drug-resistant</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Tuberculosis, drug-resistant (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral, IV:</b> 750 mg to 1 g once daily in combination with additional appropriate antituberculosis agents (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31729908']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31729908'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Duration:</b> Individualize based on rapidity of culture conversion, extent of disease, and patient-specific factors, including clinical response and toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31729908','lexi-content-ref-WHO.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31729908','lexi-content-ref-WHO.2019'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5ac615e6-688a-461c-8a9f-5e7703d06ac9">Urinary tract infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Urinary tract infection: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Cystitis, acute uncomplicated or acute simple cystitis </i>
<i>(infection limited to the bladder without signs/symptoms of upper tract, prostate, or systemic infection) (alternative agent): </i>
<b>Note:</b> Use is discouraged due to safety concerns and increasing resistance; reserve for those who have no alternative treatment options (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26926640','lexi-content-ref-FDA..2016','lexi-content-ref-Hooton.2021a','lexi-content-ref-Hooton.2021b','lexi-content-ref-21292654']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26926640','lexi-content-ref-FDA..2016','lexi-content-ref-Hooton.2021a','lexi-content-ref-Hooton.2021b','lexi-content-ref-21292654'])">Ref</a></span>). However, for men who have severe symptoms or concern for early prostate involvement, some experts prefer fluoroquinolones (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Hooton.2021b']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Hooton.2021b'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b> 250 mg once daily for 3 days (females) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>) or 5 days (males) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Hooton.2021b']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Hooton.2021b'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Urinary tract infection, complicated, (including pyelonephritis):</i>
<b>Note:</b> If the prevalence of fluoroquinolone resistance is &gt;10%, an initial dose of a long-acting parenteral antimicrobial (eg, ceftriaxone) followed by oral therapy is recommended for outpatients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Hooton.2021c','lexi-content-ref-21292654']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Hooton.2021c','lexi-content-ref-21292654'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral, IV:</b> 750 mg once daily for 5 to 7 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Hooton.2021c']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Hooton.2021c'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Missed dose:</b> Administer as soon as possible if ≥8 hours until next scheduled dose; otherwise, wait until next scheduled dose.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990717"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b> Oral, IV:</p>
<table border="1" frame="border" rules="all">
<caption style="text-align:center;">
<b>Levofloxacin Dose Adjustments in Altered Kidney Function</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead valign="middle">
<tr>
<th align="center">
<p style="text-indent:0em;">
<b>CrCl (mL/minute) </b></p></th>
<th align="center">
<p style="text-indent:0em;">If usual recommended dose is 250 mg every 24 hours</p></th>
<th align="center">
<p style="text-indent:0em;">If usual recommended dose is 500 mg every 24 hours</p></th>
<th align="center">
<p style="text-indent:0em;">If usual recommended dose is 750 mg every 24 hours<sup class="footnote-number">a</sup></p></th></tr></thead>
<tfoot valign="middle">
<tr>
<td align="center" colspan="4">
<p style="text-indent:-2em;margin-left:2em;text-align:left;">
<sup>a</sup>Treatment of tuberculosis: CrCl &gt;30 mL/minute: No dosage adjustment necessary. CrCl &lt;30 mL/minute or on hemodialysis/peritoneal dialysis: Administer 750 mg or 1 g 3 times per week (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31729908','lexi-content-ref-27516382']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31729908','lexi-content-ref-27516382'])">Ref</a></span>). Patients receiving hemodialysis 3 times/week: Administer dose after hemodialysis on dialysis days.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:left;">
<sup> b </sup>Severe infections and GFR<sub>CKD-EPI </sub>&gt;80 mL/minute/1.73 m<sup>2</sup>: Monte Carlo simulations suggest a dose of 500 mg every 12 hours may be necessary to obtain pharmacodynamic targets when minimum inhibitory concentration ≥0.5 mg/L (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28031199']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28031199'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;text-align:left;">
<sup>c</sup>When scheduled dose falls on a dialysis day, administer post dialysis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p></td></tr></tfoot>
<tbody valign="middle">
<tr>
<td align="center">
<p style="text-indent:0em;">≥50</p></td>
<td align="center">
<p style="text-indent:0em;">No dosage adjustment necessary</p></td>
<td align="center">
<p style="text-indent:0em;">No dosage adjustment necessary</p></td>
<td align="center">
<p style="text-indent:0em;">No dosage adjustment necessary<sup class="footnote-number">b</sup></p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">20 to &lt;50</p></td>
<td align="center">
<p style="text-indent:0em;">No dosage adjustment necessary</p></td>
<td align="center">
<p style="text-indent:0em;">500 mg initial dose, then 250 mg every 24 hours</p></td>
<td align="center">
<p style="text-indent:0em;">750 mg every 48 hours</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">&lt;20</p></td>
<td align="center">
<p style="text-indent:0em;">250 mg every 48 hours (except for uncomplicated UTI, where no dosage adjustment is required)</p></td>
<td align="center">
<p style="text-indent:0em;">500 mg initial dose, then 250 mg every 48 hours</p></td>
<td align="center">
<p style="text-indent:0em;">750 mg initial dose, then 500 mg every 48 hours</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Hemodialysis, intermittent (thrice weekly)<sup class="footnote-number">c</sup>: Dialyzable (21% [4-hour dialysis session utilizing high-flux dialyzers]) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21715074']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21715074'])">Ref</a></span>)</p></td>
<td align="center">
<p style="text-indent:0em;">250 mg every 48 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>)</p></td>
<td align="center">
<p style="text-indent:0em;">500 mg initial dose, then <b>either</b> 250 mg every 48 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12900817','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12900817','lexi-content-ref-Manu.1'])">Ref</a></span>) <b>or </b>125 mg every 24 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22946871']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22946871'])">Ref</a></span>) (if daily dosing improves adherence (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>))</p></td>
<td align="center">
<p style="text-indent:0em;">750 mg initial dose, then <b>either</b> 500 mg every 48 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>) <b>or </b>250 mg every 24 hours (if daily dosing improves adherence (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>))</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Peritoneal dialysis</p></td>
<td align="center">
<p style="text-indent:0em;">250 mg every 48 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>)</p></td>
<td align="center">
<p style="text-indent:0em;">500 mg initial dose, then <b>either </b>250 mg every 48 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>) <b>or </b>125 mg every 24 hours (if daily dosing improves adherence [expert opinion derived from Kanamori 2001])</p></td>
<td align="center">
<p style="text-indent:0em;">750 mg initial dose, then <b>either</b> 500 mg every 48 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>) <b>or </b>250 mg every 24 hours (if daily dosing improves adherence (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>))</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:2em;">
<b>Augmented renal clearance (measured urinary CrCl ≥130 mL/minute/1.73 m<sup>2</sup> ): </b>Augmented renal clearance (ARC) is a condition that occurs in certain critically-ill patients without organ dysfunction and with normal serum creatinine concentrations. Young patients (&lt;55 years of age) admitted post trauma or major surgery are at highest risk for ARC, as well as those with sepsis, burns, or hematologic malignancies. An 8- to 24-hour measured urinary CrCl is necessary to identify these patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29441476','lexi-content-ref-20000886']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29441476','lexi-content-ref-20000886'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Dose based on expert opinion derived from Monte Carlo simulations only (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26666946']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26666946'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Oral, IV: 750 mg loading dose followed by 500 mg every 12 hours <b>or</b> 1 g every 24 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT:</b> Drug clearance is dependent on the effluent flow rate, filter type, and method of renal replacement. Recommendations assume high-flux dialyzers and flow rates of ~1,500 to 3,000 mL/hour, and minimal residual kidney function unless otherwise noted. Appropriate dosing requires consideration of adequate drug concentrations (eg, site of infection) and consideration of initial loading doses. Close monitoring of response and adverse reactions due to drug accumulation is important.</p>
<p style="text-indent:-2em;margin-left:4em;">CVVH/CVVHD/CVVHDF: Oral, IV:</p>
<table border="1" frame="border" rules="all">
<caption style="text-align:center;">
<b>Dose Adjustments in CRRT (CVVH/CVVHD/CVVHDF)</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead valign="middle">
<tr>
<th align="center">
<p style="text-indent:0em;">
<b>If usual recommended dose is 250 mg every 24 hours </b></p></th>
<th align="center">
<p style="text-indent:-2em;margin-left:2em;">
<b>If usual recommended dose is</b> 500 mg every 24 hours</p></th>
<th align="center">
<p style="text-indent:0em;">
<b>If usual recommended dose</b> is 750 mg every 24 hours</p></th></tr></thead>
<tbody valign="middle">
<tr>
<td align="center">
<p style="text-indent:0em;">No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>)</p></td>
<td align="center">
<p style="text-indent:0em;">500 mg initial dose, then 250 mg every 24 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11396281','lexi-content-ref-18027987','lexi-content-ref-16163635']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11396281','lexi-content-ref-18027987','lexi-content-ref-16163635'])">Ref</a></span>) <b>or</b></p>
<p style="text-indent:0em;">500 mg every 48 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18027987']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18027987'])">Ref</a></span>)</p></td>
<td align="center">
<p style="text-indent:0em;">750 mg initial dose, then 500 mg every 24 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>) <b>or </b></p>
<p style="text-indent:0em;">750 mg every 48 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>)</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT:</b> Drug clearance is dependent on the effluent flow rate, filter type, and method of renal replacement. Appropriate dosing requires consideration of adequate drug concentrations (eg, site of infection) and consideration of initial loading doses. Close monitoring of response and adverse reactions due to drug accumulation is important.</p>
<p style="text-indent:-2em;margin-left:4em;">Oral, IV (dialysate flow rate 160 mL/minute, 8-hour session):</p>
<table border="1" frame="border" rules="all">
<caption style="text-align:center;">
<b>Dose Adjustments in PIRRT</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead valign="middle">
<tr>
<th align="center">
<p style="text-indent:0em;">
<b>If usual recommended dose is 250 mg every 24 hours </b></p></th>
<th align="center">
<p style="text-indent:0em;">If usual recommended dose is 500 mg every 24 hours</p></th>
<th align="center">
<p style="text-indent:0em;">If usual recommended dose is 750 mg every 24 hours</p></th></tr></thead>
<tbody valign="middle">
<tr>
<td align="center">
<p style="text-indent:0em;">No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>)</p></td>
<td align="center">
<p style="text-indent:0em;">500 mg initial dose, then 250 mg every 24 hours (after PIRRT treatment when possible) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17699357','lexi-content-ref-31342772']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17699357','lexi-content-ref-31342772'])">Ref</a></span>)</p></td>
<td align="center">
<p style="text-indent:0em;">750 mg every 48 hours (after PIRRT treatment when possible) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>)</p></td></tr></tbody></table></div>
<div class="block doha drugH1Div" id="F50988068"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">IV, Oral: There are no dosage adjustments provided in the manufacturer’s labeling (has not been studied). However, dosage adjustment unlikely due to limited hepatic metabolism.</p></div>
<div class="block arsc drugH1Div" id="F54454575"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Aortic aneurysm/aortic dissection</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Fluoroquinolones have been associated with <b>aortic aneurysm</b> and <b>aortic dissection</b> with risk of aortic aneurysm higher than aortic dissection. Overall risk with levofloxacin may be higher than ciprofloxacin and moxifloxacin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30809871','lexi-content-ref-31077091']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30809871','lexi-content-ref-31077091'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>
<i>:</i> Time-related; upregulation of matrix metalloproteinase (MMP) enzymes capable of damaging components of the extracellular matrix, including collagen and elastin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15890441','lexi-content-ref-22035890']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15890441','lexi-content-ref-22035890'])">Ref</a></span>). MMP-2 and MMP-9 have been shown to play a role in development of aneurysms via degradation of collagen fibril (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28739200']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28739200'])">Ref</a></span>). May also have a direct effect on the viability of chondrocytes and tenocytes responsible for collagen synthesis, due to generation of reactive oxygen species, caspase activation, and apoptosis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22615289','lexi-content-ref-15890441']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22615289','lexi-content-ref-15890441'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Delayed in most cases. Studies evaluating risk generally evaluated the time period of 60 days after the initiation of fluoroquinolone therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29519881']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29519881'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">• Older adults with peripheral vascular disease or a history of aneurysms, atherosclerosis, hypertension, or genetic conditions predisposing to aortic aneurysm (eg, Marfan syndrome, Ehlers-Danlos syndrome) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30213330']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30213330'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Longer courses of therapy (&gt;14 days) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30213330']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30213330'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Severe emotional or physical stress has been correlated to the onset of pain (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17950810']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17950810'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Arthropathy/arthralgia</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Arthropathy, or joint disease, has been observed in both animal and pediatric human studies following treatment with fluoroquinolone antibiotics, including levofloxacin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26865283']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26865283'])">Ref</a></span>). In a pooled safety data analysis of ~2,500 pediatric patients, musculoskeletal events including <b>arthralgia</b> were observed more frequently at 2 months and 12 months after treatment with levofloxacin than comparative treatment; no physical joint abnormalities were observed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17901792']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17901792'])">Ref</a></span>). Long-term follow-up (up to 5 years) of ~200 of the initial patients demonstrated no difference in musculoskeletal adverse events including ongoing arthropathy, between levofloxacin and comparator (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24918220']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24918220'])">Ref</a></span>). Arthropathy and arthralgias appear to resolve after discontinuation of treatment with no long-term sequelae (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24918220','lexi-content-ref-26865283']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24918220','lexi-content-ref-26865283'])">Ref</a></span>). Though the true incidence is unknown, arthropathy and arthralgia are considered to be infrequent, but potentially serious adverse reactions.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism<b>:</b></i> Unknown; several hypotheses have been proposed including inhibition of mitochondria DNA synthesis in immature chondrocytes, direct toxic effect of fluoride on cartilage, magnesium chelation and subsequent deficiency in cartilage, and defective proteoglycan and procollagen synthesis with decreased incorporation of tritiated thymidine by chondrocytes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26865283']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26865283'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset: </i>Varied; may occur within a day of initiation or months following discontinuation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17901792']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17901792'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Higher doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27940800']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27940800'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Prolonged exposure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27940800','lexi-content-ref-26865283']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27940800','lexi-content-ref-26865283'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">CNS effects/neuroexcitation</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Fluoroquinolones have been associated with a range of psychiatric and neurologic effects, from <b>dizziness</b> and <b>restlessness</b> to <b>toxic psychosis</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29702230','lexi-content-ref-21585220']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29702230','lexi-content-ref-21585220'])">Ref</a></span>). More common reactions include <b>confusion</b>, <b>agitation</b>, <b>insomnia</b>, and <b>drowsiness</b>. More severe reactions, including delusions, <b>hallucinations</b>, <b>suicidal ideation</b>, <b>suicidal tendencies</b>, and toxic psychosis are less common (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31890418']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31890418'])">Ref</a></span>). Neuroexcitation may include <b>seizure</b> in some patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19707748']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19707748'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: GABA binding disruption, NMDA binding alterations, and increased excitatory neurotransmitters (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8390432','lexi-content-ref-20397737']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8390432','lexi-content-ref-20397737'])">Ref</a></span>). Mitochondrial dysfunction has been hypothesized to contribute (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28063266']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28063266'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; neuroexcitatory phenomena generally occur in the first week of therapy, often after 2 to 3 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21585220']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21585220'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">• Older adults (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25450476']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25450476'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Kidney impairment with unadjusted or higher doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26400582']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26400582'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent therapy with nonsteroidal anti-inflammatory drugs (NSAIDs) have been associated with enhanced neuroexcitation (less risk with levofloxacin) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25450476','lexi-content-ref-21585220']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25450476','lexi-content-ref-21585220'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent theophylline (less risk with levofloxacin) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25450476']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25450476'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• History of seizures, seizure disorders, CNS disorders, or concurrent therapy with medications known to lower seizure threshold may increase risk of seizures (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26400582']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26400582'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• History of or risk factor for mental illness (eg, depression)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Clostridioides difficile infection</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<i>Clostridioides difficile</i> infection (CDI), including <b>
<i>Clostridioides difficile</i> associated diarrhea</b> and <b>
<i>Clostridioides difficile</i> colitis</b>, has been reported.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; may start on the first day of antibiotic therapy or up to 3 months postantibiotic (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22146873','lexi-content-ref-29053792']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22146873','lexi-content-ref-29053792'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">• Antibiotic exposure (highest risk factor) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.2020','lexi-content-ref-29053792','lexi-content-ref-29462280','lexi-content-ref-27216385','lexi-content-ref-29272341']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.2020','lexi-content-ref-29053792','lexi-content-ref-29462280','lexi-content-ref-27216385','lexi-content-ref-29272341'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Type of antibiotic (fluroquinolones among the highest risk) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23478961','lexi-content-ref-CDC.2020','lexi-content-ref-24755188','lexi-content-ref-23620467','lexi-content-ref-29053792','lexi-content-ref-27216385']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23478961','lexi-content-ref-CDC.2020','lexi-content-ref-24755188','lexi-content-ref-23620467','lexi-content-ref-29053792','lexi-content-ref-27216385'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Long durations in a hospital or other health care setting (recent or current) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.2020','lexi-content-ref-29053792','lexi-content-ref-29462280','lexi-content-ref-27216385','lexi-content-ref-29272341']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.2020','lexi-content-ref-29053792','lexi-content-ref-29462280','lexi-content-ref-27216385','lexi-content-ref-29272341'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Older adults (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.2020','lexi-content-ref-29053792','lexi-content-ref-29462280','lexi-content-ref-27216385','lexi-content-ref-29272341']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.2020','lexi-content-ref-29053792','lexi-content-ref-29462280','lexi-content-ref-27216385','lexi-content-ref-29272341'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Immunocompromised conditions (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.2020','lexi-content-ref-29053792','lexi-content-ref-29462280','lexi-content-ref-27216385','lexi-content-ref-29272341']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.2020','lexi-content-ref-29053792','lexi-content-ref-29462280','lexi-content-ref-27216385','lexi-content-ref-29272341'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• A serious underlying condition (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.2020','lexi-content-ref-29053792','lexi-content-ref-29462280','lexi-content-ref-27216385','lexi-content-ref-29272341']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.2020','lexi-content-ref-29053792','lexi-content-ref-29462280','lexi-content-ref-27216385','lexi-content-ref-29272341'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• GI surgery/manipulation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29462280','lexi-content-ref-27216385']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29462280','lexi-content-ref-27216385'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Antiulcer medications (eg, proton pump inhibitors and H2 blockers) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.2020','lexi-content-ref-29462280','lexi-content-ref-27216385','lexi-content-ref-29272341']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.2020','lexi-content-ref-29462280','lexi-content-ref-27216385','lexi-content-ref-29272341'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Chemotherapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.2020','lexi-content-ref-29053792','lexi-content-ref-29462280','lexi-content-ref-27216385','lexi-content-ref-29272341']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.2020','lexi-content-ref-29053792','lexi-content-ref-29462280','lexi-content-ref-27216385','lexi-content-ref-29272341'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Glucose regulation/dysglycemia</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hyperglycemia</b> and <b>hypoglycemia</b> have been associated with the use of fluoroquinolones, including levofloxacin.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Increase in insulin release via blockade of adenosine triphosphate-sensitive potassium channels in the pancreatic beta cells, but the significance at clinical concentrations has been questioned (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19073153','lexi-content-ref-24284031']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19073153','lexi-content-ref-24284031'])">Ref</a></span>). Additionally, effects on gluconeogenesis, glucose transport (via expression of GLUT-1), and mitochondrial dysfunction have been implicated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19022360','lexi-content-ref-32004540']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19022360','lexi-content-ref-32004540'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; corresponds to the initiation of therapy but may be delayed by 2 to 3 days. Events requiring emergent care or hospitalization occurred between day 3 and day 10 of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23948133']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23948133'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Patients with diabetes are at highest risk; however, cases in patients without diabetes have been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16185173']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16185173'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent therapy with hypoglycemic agents, including insulin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23948133','lexi-content-ref-16185173']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23948133','lexi-content-ref-16185173'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hepatotoxicity</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Liver injury/drug-induced liver injury: May cause liver injury (<b>hepatotoxicity</b>); both cholestatic and hepatocellular patterns are represented in reported clinical presentations (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24879988','lexi-content-ref-21356330']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24879988','lexi-content-ref-21356330'])">Ref</a></span>). Published reports include at least 1 fatal case (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24067876','lexi-content-ref-29523775']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24067876','lexi-content-ref-29523775'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Immunologic reactions account for many events; direct toxicity related to mitochondrial dysfunction and increased oxidative stress may also be responsible for some reactions (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21356330']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21356330'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; acute liver injury generally occurred within 14 days of initiation (most cases within 6 days) range of 1 to 39 days.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">• Most fatal events occurred in patients ≥65 years of age</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hypersensitivity reactions (immediate and delayed)</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity reactions include <b>anaphylaxis</b>, <b>nonimmune anaphylaxis</b> (previously called anaphylactoid reactions) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23450078','lexi-content-ref-30401472','lexi-content-ref-11130225']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23450078','lexi-content-ref-30401472','lexi-content-ref-11130225'])">Ref</a></span>) and delayed cutaneous reactions.</p>
<p style="text-indent:-2em;margin-left:4em;">Delayed cutaneous reactions include severe dermatologic reactions, <b>acute generalized exanthematous pustulosis</b>
<b>,</b>
<b>drug reaction with eosinophilia and systemic symptoms</b>, <b>Stevens-Johnson syndrome</b>, and <b>toxic epidermal necrolysis</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26238129','lexi-content-ref-19492670','lexi-content-ref-15886293','lexi-content-ref-30484869','lexi-content-ref-27634312']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26238129','lexi-content-ref-19492670','lexi-content-ref-15886293','lexi-content-ref-30484869','lexi-content-ref-27634312'])">Ref</a></span>). Less severe reactions include <b>fixed drug eruption</b> and bullous pemphigoid reactions (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22900968','lexi-content-ref-30246872']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22900968','lexi-content-ref-30246872'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Immunologically mediated organ-specific reactions include <b>pancreatitis</b>, <b>interstitial nephritis</b>, <b>hemolytic anemia</b>,<b> thrombocytopenia</b>, and some cases of hepatitis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24879988','lexi-content-ref-12841809','lexi-content-ref-12552523','lexi-content-ref-21164064','lexi-content-ref-25024854','lexi-content-ref-28403679']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24879988','lexi-content-ref-12841809','lexi-content-ref-12552523','lexi-content-ref-21164064','lexi-content-ref-25024854','lexi-content-ref-28403679'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Nonimmune anaphylaxis results from binding directly to specific receptors (MGPRX2) on mast cells and basophils, causing direct stimulation of histamine release (and other mediators) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30856392']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30856392'])">Ref</a></span>). Importantly, these cases may occur without prior exposure. In other cases, anaphylaxis may be mediated by IgE, formed with prior exposure to the drug (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14713922']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14713922'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Delayed reactions are mediated by activated T cells. Chemical activation of fluoroquinolones was not required for immune reactions to occur, which implies direct activation (pharmacologic interaction) without covalent binding to host proteins/hapten formation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16393267']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16393267'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset: </i>Anaphylaxis (nonimmune and immune): Rapid; may occur within an hour of administration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30401472']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30401472'])">Ref</a></span>). Other reactions, particularly various maculopapular cutaneous reactions or organ-specific reactions: Varied; occur after days to weeks of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15886293','lexi-content-ref-24879988','lexi-content-ref-12841809','lexi-content-ref-12552523','lexi-content-ref-21164064','lexi-content-ref-25024854','lexi-content-ref-28403679']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15886293','lexi-content-ref-24879988','lexi-content-ref-12841809','lexi-content-ref-12552523','lexi-content-ref-21164064','lexi-content-ref-25024854','lexi-content-ref-28403679'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">• Nonimmune anaphylaxis may be dose and/or infusion rate related (concentration-related) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30856392']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30856392'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Myasthenia gravis</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Fluoroquinolones, including levofloxacin, may cause an <b>exacerbation of</b>
<b>myasthenia gravis</b>. Disease exacerbations vary in severity from muscular weakness to severe compromise (myasthenic crisis characterized by acute respiratory failure) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21879778']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21879778'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Neuromuscular blockade is the most frequently cited mechanism, although alterations in mitochondrial energy production has also been suggested as a contributing mechanism (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21879778']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21879778'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Rapid; Within hours of the initiation of therapy with a fluoroquinolone (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21879778','lexi-content-ref-2224281']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21879778','lexi-content-ref-2224281'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">• Patients with myasthenia gravis (diagnosed and undiagnosed) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2224281']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2224281'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Peripheral neuropathy</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Fluoroquinolones have been associated with <b>peripheral neuropathy</b> and other effects, including axonal neuropathy and <b>Guillain-Barré syndrome</b> (GBS) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24472364','lexi-content-ref-29928218']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24472364','lexi-content-ref-29928218'])">Ref</a></span>). Associated with many types of disturbances of special senses, including several case reports indicating a very slow recovery and/or permanent state of disability (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11793615']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11793615'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Mitochondrial effects related to reactive oxygen species and apoptotic changes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19022360','lexi-content-ref-32004540','lexi-content-ref-25902267','lexi-content-ref-23825301']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19022360','lexi-content-ref-32004540','lexi-content-ref-25902267','lexi-content-ref-23825301'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; may present as early as the first day of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11793615','lexi-content-ref-26425618']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11793615','lexi-content-ref-26425618'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">• Males (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31034074']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31034074'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Older adults (&gt;60 years of age) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31034074']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31034074'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Duration of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31034074']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31034074'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Type 1 diabetes may also be a risk factor (data are limited) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29511692']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29511692'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• History of peripheral neuropathy</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Phototoxicity/photoallergy</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Phototoxicity/skin photosensitivity</b> account for a proportion of the overall cutaneous adverse reactions (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30003982']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30003982'])">Ref</a></span>). <b>Hyperpigmentation</b> (brown-grey) in areas exposed to sunlight has also been reported with levofloxacin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30261569']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30261569'])">Ref</a></span>). Levofloxacin is considered a lower risk among the fluoroquinolone class (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8320021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8320021'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Non-dose-related; immunologic. Reactive intermediates are generated by ultraviolet exposure and attach to proteins of Langerhans cells, triggering immune reactions (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10692119']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10692119'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Rapid; in a study with ofloxacin, occurred within 24 hours of initiation and sun exposure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8320021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8320021'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>• </i>Duration and intensity of sun exposure</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>• </i>Cystic fibrosis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22971191']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22971191'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>• </i>Prior phototoxic reaction to another fluoroquinolone (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9536423']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9536423'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">QT prolongation</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Fluoroquinolones may be associated with <b>prolonged QT interval on ECG</b> and ventricular arrhythmias, such as <b>torsades de pointes</b> (TdP). Levofloxacin may have a lower risk than other fluoroquinolones, particularly moxifloxacin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30368737','lexi-content-ref-12709719','lexi-content-ref-16472283']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30368737','lexi-content-ref-12709719','lexi-content-ref-16472283'])">Ref</a></span>). Change in QTc from baseline for moxifloxacin was found to be +16.34 to 17.83 ms, while the change with levofloxacin was +3.53 to 4.88 ms (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12709719']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12709719'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: May alter the rapid delayed rectifier potassium current, resulting in prolonged repolarization (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24428853']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24428853'])">Ref</a></span>). Prolonged repolarization can alter action potentials in cardiac cells and promote arrhythmogenic activity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31029713']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31029713'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; effect is concentration dependent, initially observed at supra-therapeutic doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11125032']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11125032'])">Ref</a></span>). High dose or accumulation may influence timing/concentrations.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">Drug-induced QTc prolongation/ TdP (in general)</p>
<p style="text-indent:-2em;margin-left:8em;">• Females (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14999113','lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14999113','lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Age &gt;65 years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Structural heart disease (eg, history of myocardial infarction or heart failure) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14999113','lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14999113','lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• History of drug-induced TdP (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Genetic defects of cardiac ion channels (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14999113','lexi-content-ref-23716032']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14999113','lexi-content-ref-23716032'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Congenital long QT syndrome (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14999113','lexi-content-ref-23716032']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14999113','lexi-content-ref-23716032'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Baseline QT interval prolongation (eg, &gt;500 msec) or lengthening of the QTc by ≥60 msec (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Electrolyte disturbances (eg, hypocalcemia, hypokalemia, hypomagnesemia) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14999113','lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14999113','lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Bradycardia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14999113','lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14999113','lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Hepatic impairment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14999113','lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14999113','lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Kidney impairment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14999113','lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14999113','lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Loop diuretic use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23716032']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23716032'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Sepsis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23716032']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23716032'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Concurrent administration of multiple medications (≥ 2) that prolong the QT interval or increase drug interactions that increase serum drug concentrations of QT prolonging medications (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14999113','lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14999113','lexi-content-ref-32929996'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Tendinopathy/tendon rupture</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">May cause <b>tendinopathy</b> or <b>rupture of tendon</b>. Achilles is most commonly cited, but inflammation/rupture of many other tendons (including hand, rotator cuff, biceps, and thumb) has been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26393387']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26393387'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Dose and time-related; upregulation of MMPs capable of damaging components of the extracellular matrix, including collagen and elastin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15890441','lexi-content-ref-22035890']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15890441','lexi-content-ref-22035890'])">Ref</a></span>). Direct effect on the viability of chondrocytes and tenocytes responsible for collagen synthesis, due to generation of reactive oxygen species, and caspase activation and apoptosis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22615289','lexi-content-ref-30811525','lexi-content-ref-20034766']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22615289','lexi-content-ref-30811525','lexi-content-ref-20034766'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; per the manufacturer's labeling, tendinopathy or tendon rupture may occur within hours or days of initiation or may be delayed for several months after discontinuation.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">• Age &gt;60 years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27138564']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27138564'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Corticosteroid therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27138564','lexi-content-ref-15890441']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27138564','lexi-content-ref-15890441'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Kidney failure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27138564']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27138564'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Diabetes mellitus (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27138564']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27138564'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Previous tendon disorders (eg, rheumatoid arthritis) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27138564']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27138564'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Solid organ transplant recipients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27138564']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27138564'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Strenuous physical activity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27138564']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27138564'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Longer duration of therapy and higher dosages (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27138564']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27138564'])">Ref</a></span>)</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F8401454"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Chest pain (1%), edema (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Pruritus (1%), skin rash (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (2%), constipation (3%), diarrhea (5%), dyspepsia (2%), nausea (7%), vomiting (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Vaginitis (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Candidiasis (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Injection site reaction (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Dizziness (3%), headache (6%), insomnia (4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Dyspnea (1%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Palpitations, phlebitis, syncope, ventricular arrhythmia, ventricular tachycardia</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Urticaria</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hyperglycemia, hyperkalemia, hypoglycemia</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Anorexia, <i>Clostridioides difficile</i> colitis, esophagitis, gastritis, gastroenteritis, glossitis, pancreatitis, stomatitis</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Genital candidiasis</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Anemia, granulocytopenia, thrombocytopenia</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Abnormal dreams, abnormal gait, agitation, anxiety, confusion, depression, drowsiness, hallucination, hypertonia, nightmares, paresthesia, seizure, vertigo</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia, hyperkinetic muscle activity, myalgia, skeletal pain, tremor</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Acute kidney injury</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Epistaxis</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Aortic aneurysm (rare: &lt;1%) (Meng 2018; Pasternak 2018), aortic dissection (rare: &lt;1%) (Meng 2018; Pasternak 2018), hypersensitivity angiitis, hypotension, prolonged QT interval on ECG (rare: &lt;1%) (Teng 2019), tachycardia (rare: &lt;1%), torsades de pointes (rare: &lt;1%) (Teng 2019), vasodilation</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Acute generalized exanthematous pustulosis, erythema multiforme, hyperpigmentation (rare: &lt;1%) (Connors 2018), phototoxicity (rare: &lt;1%), skin photosensitivity (rare: &lt;1%), Stevens-Johnson syndrome, toxic epidermal necrolysis</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Ageusia, <i>Clostridioides difficile</i> associated diarrhea, dysgeusia</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Casts in urine, crystalluria</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Agranulocytosis, aplastic anemia, eosinophilia, hemolytic anemia, increased INR, leukopenia, pancytopenia, prolonged prothrombin time, thrombotic thrombocytopenic purpura</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatic failure, hepatotoxicity (idiosyncratic; rare: &lt;1%) (Chalasani 2014; Gulen 2015; Schloss 2018)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylactic shock, anaphylaxis, angioedema, fixed drug eruption, nonimmune anaphylaxis, serum sickness</p>
<p style="text-indent:-2em;margin-left:4em;">Immunologic: Drug reaction with eosinophilia and systemic symptoms (Charfi 2015)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Abnormal electroencephalogram, altered sense of smell, anosmia, delirium, disorientation, disturbance in attention, encephalopathy (rare), exacerbation of myasthenia gravis, Guillain-Barre syndrome (rare: &lt;1%) (Ali 2014), increased intracranial pressure, memory impairment, nervousness, paranoid ideation, peripheral neuropathy (rare: &lt;1%; may be irreversible), psychosis, restlessness, suicidal ideation, suicidal tendencies, toxic psychosis, voice disorder</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Muscular paralysis (musculospiral) (Pan 2017), rhabdomyolysis, rupture of tendon (less frequent: ≥1% to &lt;4%) (van der Linden 2002), tendinopathy (less frequent: ≥1% to &lt;4%) (van der Linden 2002)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Blurred vision, decreased visual acuity, diplopia, scotoma, uveitis</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Hypoacusis, tinnitus</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Interstitial nephritis</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Bronchospasm, hypersensitivity pneumonitis</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever, multi-organ failure</p></div>
<div class="block coi drugH1Div" id="F8401447"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to levofloxacin, any component of the formulation, or other quinolones</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in US labeling): History of tendinopathy or tendon rupture associated with use of any quinolone antimicrobial agent</p></div>
<div class="block war drugH1Div" id="F8401448"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Superinfection: Prolonged use may result in fungal or bacterial superinfection.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with renal impairment; dosage adjustment required.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Older adult: Adverse effects (eg, hepatotoxicity, tendon rupture, QT changes, aortic dissection) may be increased in the elderly.</p>
<p style="text-indent:-2em;margin-left:4em;">• G6PD deficiency: Hemolytic reactions may (rarely) occur with fluoroquinolone use in patients with G6PD deficiency (Luzzatto 2020).</p>
<p style="text-indent:-2em;margin-left:4em;">• Pediatric: Safety of use in pediatric patients for &gt;14 days of therapy has not been studied; increased incidence of musculoskeletal disorders (eg, arthralgia, tendon rupture) has been observed in children.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Benzyl alcohol and derivatives: Some dosage forms may contain benzyl alcohol; large amounts of benzyl alcohol (≥99 mg/kg/day) have been associated with a potentially fatal toxicity ("gasping syndrome") in neonates; the "gasping syndrome" consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP ["Inactive" 1997]; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol with caution in neonates. See manufacturer's labeling.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878745"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">In pediatric patients, fluoroquinolones are not routinely first-line therapy, but after assessment of risks and benefits, can be considered a reasonable alternative for situations where no safe and effective substitute is available (eg, multidrug resistance) or in situations where the only alternative is parenteral therapy and levofloxacin offers an oral therapy option (AAP [Jackson 2016]).</p>
<p style="text-indent:0em;margin-top:2em;">Concentration of oral suspension may vary (commercially available or extemporaneous compound); use caution. Some dosage forms may contain propylene glycol; in neonates, large amounts of propylene glycol delivered orally, intravenously (eg, &gt;3,000 mg/day), or topically have been associated with potentially fatal toxicities which can include metabolic acidosis, seizures, renal failure, and CNS depression; toxicities have also been reported in children and adults including hyperosmolality, lactic acidosis, seizures, and respiratory depression; use caution (AAP 1997; Shehab 2009).</p></div>
<div class="block foc drugH1Div" id="F8408135"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 250 mg/50 mL (50 mL); 500 mg/100 mL (100 mL); 750 mg/150 mL (150 mL); 25 mg/mL (20 mL, 30 mL [DSC])</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 25 mg/mL (100 mL, 200 mL, 480 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Levaquin: 500 mg [DSC], 750 mg [DSC]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 250 mg, 500 mg, 750 mg</p></div>
<div class="block geq drugH1Div" id="F8398378"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F8408137"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (levoFLOXacin in D5W Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">250 mg/50 mL (per mL): $0.04 - $0.18</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 mg/100 mL (per mL): $0.03 - $0.15</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">750 mg/150 mL (per mL): $0.02 - $0.10</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (levoFLOXacin Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">25 mg/mL (per mL): $2.20</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (levoFLOXacin Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">25 mg/mL (per mL): $3.21</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (levoFLOXacin Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">250 mg (per each): $16.81 - $17.53</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 mg (per each): $19.27 - $20.09</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">750 mg (per each): $36.07 - $36.12</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52869223"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 5 mg/mL (50 mL, 100 mL, 150 mL); 5-5 MG/ML-% (50 mL, 100 mL, 150 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 250 mg, 500 mg, 750 mg</p></div>
<div class="block exp drugH1Div" id="F11432885"><span class="drugH1">Extemporaneous Preparations</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Commercial oral solution is available (25 mg/mL)</p>
<p style="text-indent:0em;margin-top:2em;">A 50 mg/mL oral suspension may be made with tablets and a 1:1 mixture of Ora-Plus® and strawberry syrup NF. Crush six 500 mg levofloxacin tablets in a mortar and reduce to a fine powder. Add small portions of the vehicle and mix to a uniform paste; mix while adding the vehicle in incremental proportions to <b>almost</b> 60 mL; transfer to a graduated cylinder, rinse mortar with vehicle, and add quantity of vehicle sufficient to make 60 mL. Label "shake well". Stable for 57 days when stored in amber plastic prescription bottles at room temperature or refrigerated.</p>
<div class="reference">VandenBussche HL, Johnson CE, and Fontana EM, et al, "Stability of Levofloxacin in an Extemporaneously Compounded Oral Liquid," <i>Am J Health Syst Pharm</i>, 1999, 56(22):2316-8.<span class="pubmed-id">10582824</span></div>
</div>
<div class="block admp drugH1Div" id="F52614367"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Oral: Maintain adequate hydration to prevent crystalluria or cylindruria. Administer at least 2 hours before or 2 hours after antacids containing magnesium or aluminum, sucralfate, metal cations (eg, iron), multivitamin preparations with zinc, or didanosine chewable/buffered tablets or the pediatric powder for solution.</p>
<p style="text-indent:-2em;margin-left:4em;">Tablets: May administer without regard to meals.</p>
<p style="text-indent:-2em;margin-left:4em;">Oral solution: Administer 1 hour before or 2 hours after meals.</p>
<p style="text-indent:-2em;margin-left:4em;">Missed dose: Administer as soon as possible if ≥8 hours until next scheduled dose; otherwise, wait until next scheduled dose.</p>
<p style="text-indent:-2em;margin-left:2em;">Parenteral: Administer by slow IV infusion over 60 to 90 minutes (250 to 500 mg over 60 minutes; 750 mg over 90 minutes); avoid rapid or bolus IV infusion due to risk of hypotension. Avoid administration through an intravenous line with a solution containing multivalent cations (eg, magnesium, calcium). Maintain adequate hydration to prevent crystalluria or cylindruria; not for IM, SubQ, or intrathecal administration.</p></div>
<div class="block adm drugH1Div" id="F8407067"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral:</b> Tablets may be administered without regard to meals. Oral solution should be administered at least 1 hour before or 2 hours after meals. Maintain adequate hydration of patient to prevent crystalluria. Administer at least 2 hours before or 2 hours after antacids containing magnesium or aluminum, sucralfate, metal cations (eg, iron), multivitamin preparations with zinc, or didanosine chewable/buffered tablets or the pediatric powder for solution.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV:</b> Infuse 250 to 500 mg IV solution over 60 minutes; infuse 750 mg IV solution over 90 minutes. Too rapid of infusion can lead to hypotension. Avoid administration through an intravenous line with a solution containing multivalent cations (eg, magnesium, calcium). Maintain adequate hydration of patient to prevent crystalluria or cylindruria.</p></div>
<div class="block sts drugH1Div" id="F8404706"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution for injection:</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Vial: Store at room temperature. Protect from light. Diluted solution (5 mg/mL) is stable in NS, D5W, D5NS, D5LR, D5<sup>1</sup>/<sub>2</sub>NS with 20 mEq/L KCl, Plasma-Lyte 56 in D5, or sodium lactate for 72 hours when stored at room temperature; stable for 14 days when stored under refrigeration. When frozen, stable for 6 months; do not refreeze. Do not thaw in microwave or by bath immersion.</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Premixed: Store at ≤25°C (77°F); do not freeze. Brief exposure to 40°C (104°F) does not adversely affect the product. Protect from light.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, oral solution: Store at 25°C (77°F); excursions permitted to 15°C to 30°C (59°F to 86°F).</p></div>
<div class="block meg drugH1Div" id="F8398367"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>
<p style="text-indent:-2em;margin-left:4em;">Levaquin tablets: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2020%2F020634s073lbl.pdf%23page%3D54&amp;token=C5rEv%2B8sSlTjJpUbCSSe1aV5oe5GTQuqQLly48JnS98QqNcLSlMjBQ5zIbTd6MKk6ChUIe6AUrIdYVKP%2FwDVOm4EZnhkVFalHtQCuKBIncy%2FRTflLD230%2BbxOmuHCvg3&amp;TOPIC_ID=16013" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020634s073lbl.pdf#page=54</a></p></div>
<div class="block usep drugH1Div" id="F53570618"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Treatment and prophylaxis of plague and postexposure prevention of inhalational anthrax (FDA approved for ages ≥6 months and adults); treatment of acute bacterial sinusitis, pneumonia (nosocomial and community acquired), acute bacterial exacerbation of chronic bronchitis, skin and skin structure infections (uncomplicated or complicated), chronic bacterial prostatitis, urinary tract infections (uncomplicated or complicated), and acute pyelonephritis (FDA approved in ages ≥18 years and adults). Has also been used for bacteremia prophylaxis in patients with leukemia and to treat acute otitis media, pulmonary exacerbations in patients with cystic fibrosis, multidrug-resistant tuberculosis, and exit-site or tunnel infection in patients with peritoneal dialysis catheters.</p>
<p style="text-indent:0em;margin-top:2em;">
<b>Note: </b>Because fluoroquinolones have been associated with disabling and potentially irreversible serious adverse reactions (eg, tendinopathy and tendon rupture, peripheral neuropathy, CNS effects), reserve levofloxacin for use in all patients including pediatric patients (AAP [Jackson 2016]) who have no alternative treatment options (eg, acute exacerbation of chronic bronchitis, acute bacterial sinusitis, and uncomplicated urinary tract infections in adults).</p></div>
<div class="block mst drugH1Div" id="F8398366"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Levaquin may be confused with Levoxyl, Levsin/SL, Lovenox</p>
<p style="text-indent:-2em;margin-left:4em;">LevoFLOXacin may be confused with levETIRAcetam, levodopa, Levophed, levothyroxine</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">International issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:0em;">Levaquin [Argentina, Brazil, US, Venezuela] may be confused with Lariam brand name for mefloquine [multiple international markets]</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299595"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of OAT1/3</p></div>
<div class="block dri drugH1Div" id="F8401459"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Agents with Blood Glucose Lowering Effects: Quinolones may enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects. Quinolones may diminish the therapeutic effect of Agents with Blood Glucose Lowering Effects. Specifically, if an agent is being used to treat diabetes, loss of blood sugar control may occur with quinolone use. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aminolevulinic Acid (Systemic): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Systemic). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aminolevulinic Acid (Topical): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Topical). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amiodarone: Levofloxacin-Containing Products (Systemic) may enhance the QTc-prolonging effect of Amiodarone. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amisulpride (Oral): May enhance the QTc-prolonging effect of QT-prolonging Agents (Moderate Risk).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amphetamines: May enhance the cardiotoxic effect of Quinolones.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antacids: May decrease the absorption of Quinolones. Of concern only with oral administration of quinolones. Management: Avoid concurrent administration of quinolones and antacids to minimize the impact of this interaction. Recommendations for optimal dose separation vary by specific quinolone; see full monograph for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bacillus clausii: Antibiotics may diminish the therapeutic effect of Bacillus clausii.  Management: Bacillus clausii should be taken in between antibiotic doses during concomitant therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Calcium Salts: May decrease the absorption of Quinolones. Of concern only with oral administration of both agents. Management: Consider administering an oral quinolone at least 2 hours before or 6 hours after the dose of oral calcium to minimize this interaction. Monitor for decreased therapeutic effects of quinolones during coadministration.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine.  Management: Avoid cholera vaccine in patients receiving systemic antibiotics, and within 14 days following the use of oral or parenteral antibiotics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Corticosteroids (Systemic): May enhance the adverse/toxic effect of Quinolones. Specifically, the risk of tendonitis and tendon rupture may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dabrafenib: QT-prolonging Quinolone Antibiotics (Moderate Risk) may enhance the QTc-prolonging effect of Dabrafenib.  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Delamanid: May enhance the QTc-prolonging effect of QT-prolonging Quinolone Antibiotics (Moderate Risk). QT-prolonging Quinolone Antibiotics (Moderate Risk) may enhance the QTc-prolonging effect of Delamanid. Management: Avoid concomitant use of delamanid and quinolone antibiotics if possible. If coadministration is considered to be unavoidable, frequent monitoring of electrocardiograms throughout the full delamanid treatment period should occur.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Didanosine: Quinolones may decrease the serum concentration of Didanosine. Didanosine may decrease the serum concentration of Quinolones.  Management: Administer oral quinolones at least 2 hours before or 6 hours after didanosine. Monitor for decreased therapeutic effects of quinolones, particularly if doses cannot be separated as recommended. This does not apply to unbuffered enteric coated didanosine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Domperidone: QT-prolonging Agents (Moderate Risk) may enhance the QTc-prolonging effect of Domperidone.  Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fecal Microbiota (Live) (Oral): May diminish the therapeutic effect of Antibiotics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fecal Microbiota (Live) (Rectal): Antibiotics may diminish the therapeutic effect of Fecal Microbiota (Live) (Rectal). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fluorouracil Products: QT-prolonging Quinolone Antibiotics (Moderate Risk) may enhance the QTc-prolonging effect of Fluorouracil Products.  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Haloperidol: May enhance the QTc-prolonging effect of QT-prolonging Quinolone Antibiotics (Moderate Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hydroxychloroquine: May enhance the hyperglycemic effect of Levofloxacin-Containing Products (Systemic). Hydroxychloroquine may enhance the hypoglycemic effect of Levofloxacin-Containing Products (Systemic). Hydroxychloroquine may enhance the QTc-prolonging effect of Levofloxacin-Containing Products (Systemic).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies): Antibiotics may diminish the therapeutic effect of Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Iron Preparations: May decrease the serum concentration of Quinolones. Management: Give oral quinolones at least several hours before (4 h for moxi- and sparfloxacin, 2 h for others) or after (8 h for moxi-, 6 h for cipro/dela-, 4 h for lome-, 3 h for gemi-, and 2 h for enox-, levo-, nor-, oflox-, peflox, or nalidixic acid) oral iron.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lanthanum: May decrease the serum concentration of Quinolones. Management: Administer oral quinolone antibiotics at least one hour before or four hours after lanthanum.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levoketoconazole: QT-prolonging Agents (Moderate Risk) may enhance the QTc-prolonging effect of Levoketoconazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Magnesium Salts: May decrease the serum concentration of Quinolones. Management: Administer oral quinolones several hours before (4 h for moxi/pe/spar/enox-, 2 h for others) or after (8 h for moxi-, 6 h for cipro/dela-, 4 h for lome/pe/enox-, 3 h for gemi-, and 2 h for levo-, nor-, or ofloxacin or nalidixic acid) oral magnesium salts.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methadone: Levofloxacin-Containing Products (Systemic) may enhance the QTc-prolonging effect of Methadone.  Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methoxsalen (Systemic): Photosensitizing Agents may enhance the photosensitizing effect of Methoxsalen (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methylphenidate: May enhance the cardiotoxic effect of Quinolones.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Multivitamins/Minerals (with ADEK, Folate, Iron): May decrease the serum concentration of Quinolones. Specifically, polyvalent cations in multivitamin products may decrease the absorption of orally administered quinolone antibiotics. Management: Administer oral quinolones at least 2 hours before, or 6 hours after, the dose of a multivitamin that contains polyvalent cations (ie, calcium, iron, magnesium, selenium, zinc). Monitor for decreased quinolone efficacy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Multivitamins/Minerals (with AE, No Iron): May decrease the serum concentration of Quinolones. Specifically, minerals in the multivitamin/mineral product may impair absorption of quinolone antibiotics. Management: Administer oral quinolones at least 2 hours before, or 6 hours after, the dose of a multivitamin that contains polyvalent cations (ie, calcium, iron, magnesium, selenium, zinc). Monitor for decreased therapeutic effects of quinolones.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mycophenolate: Quinolones may decrease the serum concentration of Mycophenolate. Specifically, quinolones may decrease concentrations of the active metabolite of mycophenolate. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nadifloxacin: May enhance the adverse/toxic effect of Quinolones.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents: May enhance the neuroexcitatory and/or seizure-potentiating effect of Quinolones. Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Quinolones.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ondansetron: May enhance the QTc-prolonging effect of QT-prolonging Quinolone Antibiotics (Moderate Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pentamidine (Systemic): May enhance the QTc-prolonging effect of QT-prolonging Quinolone Antibiotics (Moderate Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimozide: May enhance the QTc-prolonging effect of QT-prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Polyethylene Glycol-Electrolyte Solution: May decrease the absorption of Quinolones. Management: Give oral quinolones at least 2 hours before or at least 6 hours after polyethylene glycol-electrolyte solutions that contain magnesium sulfate (Suflave brand). Other products without magnesium do not require dose separation.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Probenecid: May decrease the excretion of Quinolones. Specifically, probenecid may decreased the renal excretion of quinolone antibiotics. Probenecid may increase the serum concentration of Quinolones.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Antidepressants (Moderate Risk): QT-prolonging Quinolone Antibiotics (Moderate Risk) may enhance the QTc-prolonging effect of QT-prolonging Antidepressants (Moderate Risk).  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Antipsychotics (Moderate Risk): QT-prolonging Quinolone Antibiotics (Moderate Risk) may enhance the QTc-prolonging effect of QT-prolonging Antipsychotics (Moderate Risk).  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Class IA Antiarrhythmics (Highest Risk): Levofloxacin-Containing Products (Systemic) may enhance the QTc-prolonging effect of QT-prolonging Class IA Antiarrhythmics (Highest Risk). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Class IC Antiarrhythmics (Moderate Risk): QT-prolonging Quinolone Antibiotics (Moderate Risk) may enhance the QTc-prolonging effect of QT-prolonging Class IC Antiarrhythmics (Moderate Risk).  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Class III Antiarrhythmics (Highest Risk): Levofloxacin-Containing Products (Systemic) may enhance the QTc-prolonging effect of QT-prolonging Class III Antiarrhythmics (Highest Risk). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-Prolonging Inhalational Anesthetics (Moderate Risk): May enhance the QTc-prolonging effect of QT-prolonging Quinolone Antibiotics (Moderate Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Kinase Inhibitors (Highest Risk): May enhance the QTc-prolonging effect of Levofloxacin-Containing Products (Systemic). Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Kinase Inhibitors (Moderate Risk): QT-prolonging Quinolone Antibiotics (Moderate Risk) may enhance the QTc-prolonging effect of QT-prolonging Kinase Inhibitors (Moderate Risk).  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Miscellaneous Agents (Highest Risk): Levofloxacin-Containing Products (Systemic) may enhance the QTc-prolonging effect of QT-prolonging Miscellaneous Agents (Highest Risk).  Management: Consider alternatives to this combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Miscellaneous Agents (Moderate Risk): May enhance the QTc-prolonging effect of QT-prolonging Quinolone Antibiotics (Moderate Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk): QT-prolonging Quinolone Antibiotics (Moderate Risk) may enhance the QTc-prolonging effect of QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk).  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Quinolone Antibiotics (Moderate Risk): May enhance the QTc-prolonging effect of other QT-prolonging Quinolone Antibiotics (Moderate Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Strong CYP3A4 Inhibitors (Highest Risk): QT-prolonging Quinolone Antibiotics (Moderate Risk) may enhance the QTc-prolonging effect of QT-prolonging Strong CYP3A4 Inhibitors (Highest Risk).  Management: Consider alternatives to this combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Strong CYP3A4 Inhibitors (Moderate Risk): QT-prolonging Quinolone Antibiotics (Moderate Risk) may enhance the QTc-prolonging effect of QT-prolonging Strong CYP3A4 Inhibitors (Moderate Risk).  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sertindole: May enhance the QTc-prolonging effect of QT-prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Strontium Ranelate: May decrease the serum concentration of Quinolones. Management: In order to minimize any potential impact of strontium ranelate on quinolone antibiotic concentrations, it is recommended that strontium ranelate treatment be interrupted during quinolone therapy.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sucralfate: May decrease the serum concentration of Quinolones. Management: Avoid concurrent administration of quinolones and sucralfate to minimize the impact of this interaction. Recommendations for optimal dose separation vary by specific quinolone.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Systemic): LevoFLOXacin (Systemic) may enhance the QTc-prolonging effect of Tacrolimus (Systemic). LevoFLOXacin (Systemic) may increase the serum concentration of Tacrolimus (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Avoid use of live attenuated typhoid vaccine (Ty21a)  in patients being treated with systemic antibacterial agents. Postpone vaccination until 3 days after cessation of antibiotics and avoid starting antibiotics within 3 days of last vaccine dose.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Verteporfin: Photosensitizing Agents may enhance the photosensitizing effect of Verteporfin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin K Antagonists (eg, warfarin): Quinolones may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zinc Salts: May decrease the serum concentration of Quinolones. Management: Give oral quinolones at several hours before (4 h for moxi- and sparfloxacin, 2 h for others) or after (8 h for moxi-, 6 h for cipro/dela-, 4 h for lome-, 3 h for gemi-, and 2 h for enox-, levo-, nor-, pe- or ofloxacin or nalidixic acid) oral zinc salts.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block foi drugH1Div" id="F51073434"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;display:inline">Administration with food prolonged time to peak by ~1 hour and decreased the peak concentration by ~14% and ~25% for the tablet and oral solution, respectively. Management: Tablet may be administered without regard to food; oral solution should be administered at least 1 hour before or 2 hours after food.</p></div>
<div class="block dic drugH1Div" id="F8407066"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Tablets may be taken without regard to meals. Oral solution should be administered on an empty stomach (at least 1 hour before or 2 hours after a meal).</p></div>
<div class="block pri drugH1Div" id="F8400752"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Levofloxacin crosses the placenta and can be detected in the amniotic fluid and cord blood (Ozyüncü 2010a; Ozyüncü 2010b).</p>
<p style="text-indent:0em;margin-top:2em;">Based on available data, an increased risk of major birth defects, miscarriage, or other adverse fetal and maternal outcomes have not been observed following levofloxacin use during pregnancy (Acar 2019; Yefet 2018; Ziv 2018).</p>
<p style="text-indent:0em;margin-top:2em;">Levofloxacin is an alternative agent for treatment of drug-resistant tuberculosis. Tuberculosis (TB) disease (active TB) is associated with adverse fetal outcomes, including intrauterine growth restriction, low birth weight, preterm birth, and perinatal death (Esmail 2018; Miele 2020), as well as adverse maternal outcomes, including increased risks for anemia and cesarean delivery. Placental transmission may rarely occur with active maternal disease (Miele 2020). Data are limited for use of second-line drugs in pregnancy (ie, fluroquinolones). Individualized regimens should be utilized to treat multidrug-resistant tuberculosis in pregnant patients; evidence to support a specific regimen is not available. Based on susceptibility testing, levofloxacin may be used to treat multidrug-resistant TB during pregnancy when needed (ATS/CDC/ERS/IDSA [Nahid 2019]; HHS [OI adult 2020]; WHO 2020).</p>
<p style="text-indent:0em;margin-top:2em;">Levofloxacin is approved to reduce the incidence or disease progression of inhalational anthrax (postexposure). Untreated anthrax infection during pregnancy is associated with preterm labor, fetal distress, and fetal loss. However, levofloxacin is not the preferred fluoroquinolone for the prophylaxis or treatment of anthrax in pregnant and postpartum patients (Meaney-Delman 2014).</p>
<p style="text-indent:0em;margin-top:2em;">Untreated plague (<i>Yersinia pestis</i>) infection in pregnant patients may result in hemorrhage (including postpartum hemorrhage), maternal and fetal death, preterm birth, and stillbirth. Limited data suggest maternal-fetal transmission of <i>Y. pestis</i> can occur if not treated. Pregnant patients should be treated for <i>Y. pestis; </i>parenteral antibiotics are preferred for initial treatment when otherwise appropriate. Levofloxacin is one of the fluoroquinolones recommended for use (in combination with an aminoglycoside) for treating pregnant patients with bubonic, pharyngeal, pneumonic, or septicemic plague. Recommendations for treating pregnant patients with plague meningitis are the same as in nonpregnant patients. Levofloxacin may also be used for pre- and postexposure prophylaxis in pregnant patients exposed to <i>Y. pestis</i> (CDC [Nelson 2021]).</p>
<p style="text-indent:0em;margin-top:2em;">Antibiotics other than levofloxacin are recommended for the treatment of uncomplicated urinary tract infections and pyelonephritis during pregnancy (Betschart 2020).</p></div>
<div class="block mopp drugH1Div" id="F53570613"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Evaluation of organ system functions (renal, hepatic, and hematopoietic) is recommended periodically during therapy; the possibility of crystalluria should be assessed, hydration status; WBC and signs of infection; number and type of stools/day for diarrhea; signs and symptoms of tendonitis</p></div>
<div class="block pha drugH1Div" id="F8404710"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">As the S(-) enantiomer of the fluoroquinolone, ofloxacin, levofloxacin, inhibits DNA-gyrase in susceptible organisms thereby inhibits relaxation of supercoiled DNA and promotes breakage of DNA strands. DNA gyrase (topoisomerase II), is an essential bacterial enzyme that maintains the superhelical structure of DNA and is required for DNA replication and transcription, DNA repair, recombination, and transposition.</p></div>
<div class="block phk drugH1Div" id="F8404755"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Absorption: Rapid and complete; levofloxacin oral tablet and solution formulations are bioequivalent </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Distribution: Widely distributed in the body, including blister fluid, skin tissue, macrophages, prostate, and lung tissue; CSF concentrations ~15% of serum concentrations </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">V<sub>d</sub>: (Chien 2005):</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Infants ≥6 months, Children, and Adolescents ≤16 years: Mean range: 1.44 to 1.57 L/kg; reported values not statistically different between pediatric age subgroups; distribution not age-dependent </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Adults: 1.27 L/kg </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Protein binding: ~24% to 38%; primarily to albumin</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Metabolism: Minimally hepatic</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Bioavailability: ~99%</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Half-life elimination:</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Infants ≥6 months and Children ≤5 years: ~4 hours (Chien 2005)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Children 5 to 10 years: 4.8 hours (Chien 2005)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Children 10 to 12 years: 5.4 hours (Chien 2005)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Children 12 to 16 years: 6 hours (Chien 2005)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Adults: ~6 to 8 hours</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Adults, renal impairment: 27 ± 10 hours (CrCl 20 to 49 mL/minute); 35 ± 5 hours (CrCl &lt;20 mL/minute)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Time to peak, serum: Oral: 1 to 2 hours</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Excretion: Urine (~87% as unchanged drug, &lt;5% as metabolites); feces (&lt;4%)</p>
<p style="text-indent:-2em;margin-left:2em;">Clearance: IV (Chien 2005): </p>
<p style="text-indent:-2em;margin-left:4em;">Infants and Children 6 months to 2 years: 0.35 ± 0.13 L/hour/kg</p>
<p style="text-indent:-2em;margin-left:4em;">Children 2 to 5 years: 0.32 ± 0.08 L/hour/kg</p>
<p style="text-indent:-2em;margin-left:4em;">Children 5 to 10 years: 0.25 ± 0.05 L/hour/kg</p>
<p style="text-indent:-2em;margin-left:4em;">Children 10 to 12 years: 0.19 ± 0.05 L/hour/kg</p>
<p style="text-indent:-2em;margin-left:4em;">Children 12 to 16 years: 0.18 ± 0.03 L/hour/kg</p>
<p style="text-indent:-2em;margin-left:4em;">Adults: 0.15 ± 0.02 L/hour/kg</p></div>
<div class="block phksp drugH1Div" id="F51198321"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Renal impairment: Cl is reduced and half-life prolonged in patients with CrCl less than 50 mL/minute.</p>
<p style="text-indent:-2em;margin-left:2em;">Anti-infective considerations:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Parameters associated with efficacy:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Concentration dependent, associated with AUC<sub>24</sub>/minimum inhibitory concentration (MIC), goal: &gt;87 (90% positive predictive value for pathogen eradication) (Cojutti 2017; Drusano 2004); and C<sub>max</sub> (peak)/MIC, goal ≥12 (clinical and microbiologic cures) (Abdul-Aziz 2020; Preston 1998). <b>Note: </b>In critically ill patients, some experts recommend AUC<sub>24</sub>/MIC goal &gt;125 to 250 (Abdul-Aziz 2020).</p>
<p style="text-indent:-2em;margin-left:8em;">Organism specific:</p>
<p style="text-indent:-2em;margin-left:10em;">
<i>S. pneumoniae</i>: AUC<sub>24</sub>/MIC ≥30 (bactericidal) (Ambrose 2001; Garrison 2003; Lacy 1999; Lister 1999).</p>
<p style="text-indent:-2em;margin-left:10em;">
<i>Mycobacterium tuberculosis</i>: AUC<sub>24</sub>/MIC ≥146 (bacteriostatic at 24 hours) (Deshpande 2018).</p>
<p style="text-indent:-2em;margin-left:10em;">
<i>Pseudomonas aeruginosa</i>: AUC<sub>24</sub>/MIC ≥80 (bactericidal) (Griffith 2006).</p>
<p style="text-indent:-2em;margin-left:4em;">Expected drug exposure in patients with normal renal function:</p>
<p style="text-indent:-2em;margin-left:6em;">AUC:</p>
<p style="text-indent:-2em;margin-left:8em;">Adults (multiple dose): AUC<sub>24</sub>:</p>
<p style="text-indent:-2em;margin-left:10em;">500 mg daily: Oral: 47.5 ± 6.7 mg•hour/L; IV: 54.6 ± 11.1 mg•hour/L.</p>
<p style="text-indent:-2em;margin-left:10em;">750 mg daily: Oral: 90.7 ± 17.6 mg•hour/L; IV: 108 ± 34 mg•hour/L.</p>
<p style="text-indent:-2em;margin-left:6em;">C<sub>max </sub>(peak):</p>
<p style="text-indent:-2em;margin-left:8em;">Pediatric patients:</p>
<p style="text-indent:-2em;margin-left:10em;">7 mg/kg (single dose) (Chien 2005):</p>
<p style="text-indent:-2em;margin-left:12em;">Infants and children 6 months to &lt;5 years of age: Oral: 4.21 to 4.56 mg/L; IV: 5.19 to 6.02 mg/L.</p>
<p style="text-indent:-2em;margin-left:12em;">Children and adolescents 5 to 16 years of age: Oral: 3.99 to 4.76 mg/L; IV: 6.12 to 7.3 mg/L.</p>
<p style="text-indent:-2em;margin-left:10em;">15 mg/kg daily (steady state) (Thee 2014):</p>
<p style="text-indent:-2em;margin-left:12em;">Infants and children &lt;6 years of age: Oral: Median: 6.86 to 7 mg/L (interquartile range: 4.69 to 8.06 mg/L).</p>
<p style="text-indent:-2em;margin-left:12em;">Children 6 to 8 years of age: Oral: Median: 4.98 mg/L (interquartile range: 4.52 to 7.48 mg/L).</p>
<p style="text-indent:-2em;margin-left:8em;">Adults (multiple dose):</p>
<p style="text-indent:-2em;margin-left:10em;">500 mg daily: Oral: 5.7 ± 1.4 mg/L; IV: 6.4 ± 0.8 mg/L.</p>
<p style="text-indent:-2em;margin-left:10em;">750 mg daily: Oral: 8.6 ± 1.9 mg/L; IV: 12.1 ± 4.1 mg/L.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Postantibiotic effect: </i>Bacterial killing continues after levofloxacin concentration falls below the MIC of targeted pathogen and varies based on the organism; generally, 1 to 3 hours (Fu 1992; Houston 1994; Licata 1997; Spangler 1998).</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F10961985"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Evoxil | Levocrat | Levofloxacin kabi | Matador | Tavanic</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Farmbiotic | Grepiflox Iv Premix | Levaquin | Levofloxacina Hlb | Levofloxacina norgreen | Levofloxacina pharmavial | Levofloxacina richet | Misile | Tavanic | Teraquin | Unilevo | Xaflo</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Levofloxacin actavis | Levofloxacin hikma | Levofloxacin hospira | Levofloxacin kabi | Tavanic</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">3-F | Anlev | Bacnil | Evo | Leevotin | Leo | Levobac | Levoflox | Levogen | Levoking | Levolex | Levoquin | Levotab | Levox | Levoxin | Lovicin | Orlev | Resquin | Trevox</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Levofloxacin ab | Levofloxacin B. Braun | Levofloxacin hospira | Levofloxacine | Levofloxacine actavis | Levofloxacine eg | Levofloxacine fresenius kabi | Levofloxacine Sandoz | Levofloxacine Teva | Tavanic</span>;</li>
<li>
<span class="countryCode">(BF)</span> <span class="country">Burkina Faso</span><span class="countrySeparator">: </span><span class="drugName">Leflumax | Levoas | Levobact | Levocine | Livozed | Tavanic | Viklevo</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Flexid | Levalox | Levofloxacin Billev Pharma | Levofloxacin kabi | Levofloxan | Levor | Levoxa | Tavanic</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Alevo | Levaflox | Levofloxacino | Levofloxacino hemi hidratado | Levotac | Levox | Quinolevi | Tavanic</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Levofloxacin fresenius | Levofloxacin labatec | Levofloxacin Mepha | Levofloxacin teva | Tavanic</span>;</li>
<li>
<span class="countryCode">(CI)</span> <span class="country">Côte d'Ivoire</span><span class="countrySeparator">: </span><span class="drugName">Floxium | Levoas | Levobact | Levoray | Livozed | Sharolev | Tavanic | Ticolev | Viklevo | Zoline</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Recamicina | Tavanic</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Ai xing | Ai zuo xin | AN FAN ZHENG | Bi lai xin | Bi tuo | Cravit | De er fu xing | Di nuo xin | Hai li jian | Heng ao | Jing bi tuo xin | Lai li xin | Lai mei xing | Le lang | Leflox | Levofloxacin and Sodium Chloride | Levofloxacin hydrochloride and glucose | Levofloxacin lactate and glucose | Levofloxacin mesylate and sodium chloride | Li fu xing | Qiang pu xin | Qing kang | Quan ying | Sha yan | Te fu bi ke | Tong lin | Tuo bi lai | Wei sha xin | Xi pu ke ding | Yi nuo ke | Yi pin | You pu luo kang | Zuo ke</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Faxov | Fluoning | Levaquin | Levofloxacina | Levofloxacino | Levovax | Nirliv | Safelevo | Sopril | Tavanic | Termedol | Truxa | Uroflav</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Levaxela | Levofloxacin kabi | Levofloxacin mylan | Tavanic</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Levoflox denk | Levofloxacin actavis | Levofloxacin Amneal | Levofloxacin bioeq pharma | Levofloxacin eberth | Levofloxacin EVER | Levofloxacin Hameln | Levofloxacin hikma | Levofloxacin hospira | Levofloxacin Infomed Fluids | Levofloxacin kabi | Levofloxacin Lyomark | Levofloxacin normon | Levofloxacin Teva | Tavanic</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Bifloxel il | Biolexina | Bredelin | Cinacol | Elequine | Evocs iii | Floxlevo | Glevo | Iberfloxa | Kevol | Levanol | Levo | Levobiotic | Levofel | Levofloxacina | Levofloxacina feltrex | Levofloxacino | Levofran | Levoquinol | Maxifer | Neumoflox | Primeris | Talevoxin | Tavanic | Zinaflox</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Astefor | Elequine | Evocs iii | Fluoning | Grepiflox | Levofloxacino | Recamicina | Tavanic | Truxa</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Tavanic</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Alfacef | Alfaspect | Kevork | Larivex | Lee-flox | Levoflotanet | Levoflox | Levoxin | Mepafloxin | Mylotarg | Targofloxin | Tavacin | Tavanic | Tavoniflox | Unibiotic | Venaxan</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Levofloxacino accord | Levofloxacino actavis | Levofloxacino Altan | Levofloxacino aurovitas | Levofloxacino b. braun | Levofloxacino Biomendi | Levofloxacino combino pharm | Levofloxacino G.E.S. | Levofloxacino hospira | Levofloxacino Ips | Levofloxacino kabi | Levofloxacino kern pharma | Levofloxacino Normon | Levofloxacino Stada | Levofloxacino teva | Tavanic</span>;</li>
<li>
<span class="countryCode">(ET)</span> <span class="country">Ethiopia</span><span class="countrySeparator">: </span><span class="drugName">Levoflox denk | Levofloxacin</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Levofloksasiini Teva | Levofloxacin fresenius | Tavanic</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Levofloxacine actavis | Levofloxacine arrow | Levofloxacine eg | Levofloxacine hospira | Levofloxacine Kabi | Levofloxacine Mylan | Tavanic</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Evoxil | Levofloxacin | Tavanic</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Floxator | Levofloxacin/cooper | Levofloxacin/Generics | Levofloxacin/kabi | Levofloxacin/pharmanel | Levofloxacin/teva | Levolacin | Levoprolin | Lexacin | Talerin | Tavanic | Vlofinox | Zirotan</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Celevox | Cralevo | Cravit | Jecefarma levofloxacin | Leflox | Lemed | Leo | Leofort | Leovid | Levofloxacin Teva | Levofloxacina | Levoxa | Vick-Levofloxacin | Zilee</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Flexid | Levalox</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Levofloxacin altan | Levofloxacin kabi | Levofloxacin sandoz | Levofloxacin Teva | Levoxa | Tavanic</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Cravit | Cravox | Difloxin | Elvacin | Farlev | Floxacap | Floxacom | Lefos | Lekuicin | Levin | Levocin | Levonic | Levores | Levovid | Levoxal | Lexa | Lq | Mosardal | Nislev | Nufalev | Prolecin | Prolevox | Reskuin | Rilevo | Tevox | Volequin | Volox</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Levofloxacin | Tavanic</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Alevo | Altimate | Baroliv | Daflox | Defolin | Diolof | Estalox 500 | Evos | Fynal | Glevo | Gufilox | Hblivo | Joycin | Klovox | L Cin | L-oxo | Lamiwin | Lazanol | Lcr | Lee | Leflox | Lefoxa | Lenova | Leof | Leon | Levac | Levnix | Levobact | Levocad | Levocar | Levocide | Levocron | Levoct | Levoday | Levoflacin | Levoflox | Levoject | Levolab | Levolic | Levomac | Levonij | Levonil | Levopen | Levopil | Levopride | Levorun | Levoslog | Levostat | Levotas | Levowok | Levox | Levoxyn | Lexiflox | Lfx | Livorock | Lovolkem | Loxof | Lquin | Lxl | Monoflox | Olevo | Plazen | Quinocin | Qure | Tavanic | Uribact | Wibatol | Zevo | Zilee</span>;</li>
<li>
<span class="countryCode">(IQ)</span> <span class="country">Iraq</span><span class="countrySeparator">: </span><span class="drugName">Levocin | Levoneer | Levosam | Levoxacin awa</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Fovex | Levixiran | Levofloxacina | Levofloxacina actavis | Levofloxacina aurobindo | Levofloxacina Aurobindo Pharma Italia | Levofloxacina B. Braun | Levofloxacina Hospira | Levofloxacina kabi | Levofloxacina Mylan | Levofloxacina teva italia | Levoxacin | Prixar | Tavanic</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Lefort | Levoflox | Levonic | Loxamox | Tavanic</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Cravit | Levofloxacin dsep | Levofloxacin kcc | Levofloxacin meiji | Levofloxacin OD | Levofloxacin pfizer | Levofloxacin takata | Levofloxacin takeda teva</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Aarleflox | Ablevox | Anflox | Evo | Flovanis | Gen levo | Glevonix | L bac | L vxin | Lamiwin | Leeflox | Leflox | Levcin | Levo | Levo g | Levobact | Levocil | Levoday | Levofloxacin | Levomac | Levomegh | Levoquin | Levostand | Levotop | Levox | Levoxcin | Lexx | Livota | Livota 500 | Lotor | Mlevo | Mydawa levofloxacin | Nirliv | Resquin | Safloxa | Starlev | Tavanic | Uvex | Vofax | Vofax plus | Welquine | Zolevox</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Cravit | Hawon Levofloxacin | Highloxin | Jw levofloxacin | Lectacin | Leflox | Lefocin | Lefoxacin | Lepocin | Levloxin | Levocacin | Levofexin | Levofle | Levofloxacin cj | Levofloxacin cjc | Levofloxin | Levokacin | Levoloxin | Levoroxin | Levox | Melevox | Samsung levofloxacin | Talerin | Yooyoung levofloxacin</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Levoflox | Tavanic</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Lemed | Levoflox | Levolone | Levomed | Loxamox | Matador | Tavanic</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Levalox | Tavanic</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Levalox | Levofloxacin kabi | Tavanic</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Avaquin | Tavanic</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Adenasa | Aqulev | Atenual asf | Avotax | Bredelin | Cina | Elequine | Evocs iii | Fevasan | Flevox | Floxinobest | Fluoning | Lefarex | Lefloxin | Levofloxacina | Levofloxacino | Levofloxacino Hormona | Levofloxacino Loeffler | Livodistan | Maxiplina | Ovelquin | Pectrimal | Prosxaflo | Proxsaflo | Quinofres | Sibofix | Solofelx | Tavanic | Termedol | Uniquin | Valulen | Voflolevag</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Cravit | Glevo | Levofloxacin kabi | Levofloxol | Levores | Loxof</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Agabaxin | Amakin levofloxacin | Aspeflox | Biomegracin | Biopharma levofloxacin | Chezflox | Colevo | Devofloxin | Flexylevo | Glevo | Gorziflox | Grandlevo | Imbact | Inlevo | Justeen levofloxacin hemihydrate | L flox | Lekov | Leolin | Levda | Levocef | Levofloxacin | Levomal | Levomark | Levoneth | Levoquin | Levoseal | Lvz | S flox | Tavanic | Unoflox | Xavocin</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Levofloxacine | Tavanic</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Levaquin | Levofloxacin B.Braun | Tavanic | Tavanic orifarm</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Alevokem | Floxalab | Glevo | Gubiot | Levofloxacino | Levoproxol | Levoxin | Lexflonor | Ponaris | Q flox | Tavanic</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Axa levo | Ceflox | Diafloxcin | Flevoxcin | Floxel | Floxiprime | Glevo | Kingfloxin | Lefloxin | Lefoxin | Levobact | Levocin | Levonex | Levores | Levox | Levoxin | Levoxl | Levozef | Levozys | Loxeva | Mylevo iv | Pneumocal | Reslevo | Talerin | Teravox</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Adlevo | Aksolox | Alenolive | Anlev | Apeflox | Asteflox | Aurofloc | Bactlos | Benalox | Bestlevo | Bexus | Brent | Brodin | Celador | Ck quin | Craflox | Cravit | Dynaquin | Effiflox | Everbact | F oxacin | Faasquin | Farlev | Floquin | Floxasan | Fuvelox | Glit | Halet | Isoflox | Jevelexin | Kamflox | Kavoflox | Klust | Lavilox | Lcyn | Lebact | Lecord | Ledric | Lefexy | Leflocin | Leflotec | Leflox | Lefoxin | Lefozet | Lemit | Leocin | Leovin | Leron | Lesim | Letob | Leufex | Levelone | Levetazet | Levite | Levler | Levo | Levobay | Levocil | Levodor | Levolis | Levomac | Levomir | Levon | Levoquin | Levort | Levorx | Levos | Levosafe | Levovis | Levox | Lexoquin | Locus | Lotoflox | Lovenox | Lupin iv | Lurk | Meryquin | Moslve | Neumo | Novaeflox | Olevo | Ovelcin | Palflox | Pelikan | Pelromet | Protektin | Pulmoflox | Q lip | Qlev | Quest | Qumic | Radilev | Raylox | Relvo | S flox | Saiflox | Somaflox | Stanflox | Starlev | Tavanic | Teflox | Thelevo | Trig | Tycho | Uniquin | Valence | Vebex | Veloft | Veloft ds | Vizor | Votec | Warior | Winflox | Xeflox</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Lefox | Levalox | Levofloxacin kabi | Levofloxacin novofarm | Levofloxacin sandoz | Levoxa | Tavanic</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Levaquin</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Levofloxacina actavis | Levofloxacina Aurovitas | Levofloxacina basi | Levofloxacina ciclum | Levofloxacina farmoz | Levofloxacina Generis | Levofloxacina hikma | Levofloxacina Hospira | Levofloxacina kabi | Levofloxacina normon | Levofloxacina teva | Tavanic</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Levoflox | Levofloxacina richet | Recamicina | Tavanic</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Advaquin | Avicare | Avoxin | Evoxil | Levoflox | Levonic | Levox | Matador | Nevotic | Oxalev | Tavanic | Velox | Ziquin</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Cenomar | Evolox | Levalox | Levofloxacina infomed | Tavanic</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Ashlev | Bactoflox | Eleflox | Flexid | Glevo | Ivacine | Leflobact | Leflox alium | Lefsan | Leobag | Levoflox | Levofloxabol | Levofloxacin | Levofloxacin nova | Levofloxacin Teva | Levolet r | Levotech | Maclevo | Remedia | Signicef | Tavanic</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Bonlevo | Lavoxin | Levodis | Levonic | Loxamox | Tavanic</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Tavanic</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Cravit | Levofloxacin kabi</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Levofloksacin kabi | Tavanic</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Levalox | Levofloxacin actavis | Levofloxacin kabi | Levofloxacin mylan | Tavanic</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Biopharm levo | Cravit | Lefloxin | Lequinox | Levofexin | Levoflox Sinensix | Levofloxacin teva | Levomac | Levores | Levox | Loxof</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Levoflox | Tavacet</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Acomet | Cravit | Floxilevo | Lefox | Levoject | Levoxipolin | Lexsan | Lievo | Multiflex levoflex | Ravivo | Tavanic</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Cravit | Leflodal | Lefxin | Levofor | Levolosacin | Levox | Levoxacin | Lexacin | Lflocin | Vorotal</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Abiflox | Euroflox | Floxium | Glevo V/V | L-flox | Leflocin | Levaxela | Levo | Levo fk | Levobax | Levocin n | Levoflox | Levofloxacin | Levofloxacin Darnitsa | Levofloxacin euro | Levofloxacin novofarm | Levofloxacin vista | Levoftor | Levomac | Levopro | Levotor | Levoximed | Loxof | Remedia | Supralev | Tavanik | Tigeron | Zolev | Zolev infusion</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Aarleflox | Ablevox | Axa levo | Glevo | Glevo 500 | Leflocin | Levobact | Levocin | Levoflox denk | Levolife | Matador | Respiquin | Safelevo | Venaxan | Welquine</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Levaquin | Levoflaxin | Levoflox | Tavanic</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Ifos | Leflox | Levamox | Levaquin | Levofloxacina | Levolet | Levonic | Levonika | Locikline | Tavanic</span>;</li>
<li>
<span class="countryCode">(VN)</span> <span class="country">Viet Nam</span><span class="countrySeparator">: </span><span class="drugName">Avicemor | Bivelox | Livran | Loximat</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Artav | Aspen Levofloxacin | Levofloxacin fresenius | Levofloxacin winthrop | Levonic | Macleods levofloxacin | Spec levofloxacin | Tavanic</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Glevo | Levin | Levobact | Safelevo | Uvex</span>;</li>
<li>
<span class="countryCode">(ZW)</span> <span class="country">Zimbabwe</span><span class="countrySeparator">: </span><span class="drugName">Levox</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-32383061">
<a name="32383061"></a>Abdul-Aziz MH, Alffenaar JC, Bassetti M, et al; Infection Section of European Society of Intensive Care Medicine (ESICM); Pharmacokinetic/pharmacodynamic and Critically Ill Patient Study Groups of European Society of Clinical Microbiology and Infectious Diseases (ESCMID); Infectious Diseases Group of International Association of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT); Infections in the ICU and Sepsis Working Group of International Society of Antimicrobial Chemotherapy (ISAC). Antimicrobial therapeutic drug monitoring in critically ill adult patients: a position paper. <i>Intensive Care Med.</i> 2020;46(6):1127-1153. doi:10.1007/s00134-020-06050-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/32383061/pubmed" id="32383061" target="_blank">32383061</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24428853">
<a name="24428853"></a>Abo-Salem E, Fowler JC, Attari M, et al. Antibiotic-induced cardiac arrhythmias. <i>Cardiovasc Ther</i>. 2014;32(1):19‐25. doi:10.1111/1755-5922.12054<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/24428853/pubmed" id="24428853" target="_blank">24428853</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30738954">
<a name="30738954"></a>Acar S, Keskin-Arslan E, Erol-Coskun H, Kaya-Temiz T, Kaplan YC. Pregnancy outcomes following quinolone and fluoroquinolone exposure during pregnancy: a systematic review and meta-analysis. <i>Reprod Toxicol</i>. 2019;85:65-74. doi: 10.1016/j.reprotox.2019.02.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/30738954/pubmed" id="30738954" target="_blank">30738954</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Agha.2020">
<a name="Agha.2020"></a>Agha R, Goldberg MB. Shigella infection: treatment and prevention in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. September 16, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11487763">
<a name="11487763"></a>Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/11487763/pubmed" id="11487763" target="_blank">11487763</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30208456">
<a name="30208456"></a>Alexander S, Fisher BT, Gaur AH, et al. Effect of levofloxacin prophylaxis on bacteremia in children with acute leukemia or undergoing hematopoietic stem cell transplantation: a randomized clinical trial. <i>JAMA</i>. 2018;320(10):995-1004. doi:10.1001/jama.2018.12512<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/30208456/pubmed" id="30208456" target="_blank">30208456</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24472364">
<a name="24472364"></a>Ali AK. Peripheral neuropathy and Guillain-Barré syndrome risks associated with exposure to systemic fluoroquinolones: a pharmacovigilance analysis. <i>Ann Epidemiol</i>. 2014;24(4):279‐285. doi:10.1016/j.annepidem.2013.12.009<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/24472364/pubmed" id="24472364" target="_blank">24472364</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11557471">
<a name="11557471"></a>Ambrose PG, Grasela DM, Grasela TH, Passarell J, Mayer HB, Pierce PF. Pharmacodynamics of fluoroquinolones against Streptococcus pneumoniae in patients with community-acquired respiratory tract infections. <i>Antimicrob Agents Chemother</i>. 2001;45(10):2793-2797. doi:10.1128/AAC.45.10.2793-2797.2001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/11557471/pubmed" id="11557471" target="_blank">11557471</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-AAP.1">
<a name="AAP.1"></a>American Academy of Pediatrics (AAP). In: Kimberlin DW, Brady MT, Jackson MA, Long SA, eds. <i>Red Book: 2018 Report of the Committee on Infectious Diseases</i>. 31st ed. Itasca, IL: American Academy of Pediatrics; 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12628877">
<a name="12628877"></a>Amsden GW, Baird IM, Simon S, Treadway G. Efficacy and safety of azithromycin vs levofloxacin in the outpatient treatment of acute bacterial exacerbations of chronic bronchitis. <i>Chest</i>. 2003;123(3):772-777.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/12628877/pubmed" id="12628877" target="_blank">12628877</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27060684">
<a name="27060684"></a>Anderson PO, Sauberan JB. Modeling drug passage into human milk. <i>Clin Pharmacol Ther</i>. 2016;100(1):42-52.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/27060684/pubmed" id="27060684" target="_blank">27060684</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26393387">
<a name="26393387"></a>Arabyat RM, Raisch DW, McKoy JM, Bennett CL. Fluoroquinolone-associated tendon-rupture: a summary of reports in the Food and Drug Administration's adverse event reporting system. <i>Expert Opin Drug Saf</i>. 2015;14(11):1653‐1660. doi:10.1517/14740338.2015.1085968<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/26393387/pubmed" id="26393387" target="_blank">26393387</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17133154">
<a name="17133154"></a>Arguedas A, Dagan R, Pichichero M, et al. An open-label, double tympanocentesis study of levofloxacin therapy in children with, or at high risk for, recurrent or persistent acute otitis media. <i>Pediatr Infect Dis J</i>. 2006;25(12):1102-1109. doi:10.1097/01.inf.0000246828.13834.f9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/17133154/pubmed" id="17133154" target="_blank">17133154</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Aronoff.1">
<a name="Aronoff.1"></a>Aronoff GR, Bennett WM, Berns JS, et al. <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>, 5th ed. Philadelphia, PA: American College of Physicians; 2007.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Berbari.2019">
<a name="Berbari.2019"></a>Baddour LM, Chen AF. Prosthetic joint infection: Treatment. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed May 16, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Baddour.1">
<a name="Baddour.1"></a>Baddour LM, Harper M. Animal bites (dogs, cats, and other mammals): Evaluation and management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed July 20, 2021a.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Baddour.2">
<a name="Baddour.2"></a>Baddour LM, Harper M. Human bites: evaluation and management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed September 27, 2021b.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27080992">
<a name="27080992"></a>Barlam TF, Cosgrove SE, Abbo LM, et al. Implementing an antibiotic stewardship program: guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America. <i>Clin Infect Dis</i>. 2016;62(10):e51‐e77. doi:10.1093/cid/ciw118<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/27080992/pubmed" id="27080992" target="_blank">27080992</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22615289">
<a name="22615289"></a>Barnhill AE, Brewer MT, Carlson SA. Adverse effects of antimicrobials via predictable or idiosyncratic inhibition of host mitochondrial components. <i>Antimicrob Agents Chemother</i>. 2012;56(8):4046‐4051. doi:10.1128/AAC.00678-12<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/22615289/pubmed" id="22615289" target="_blank">22615289</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Barshak.1">
<a name="Barshak.1"></a>Barshak MB. Antimicrobial approach to intra-abdominal infections in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed April 14, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19707748">
<a name="19707748"></a>Bellon A, Perez-Garcia G, Coverdale JH, Chacko RC. Seizures associated with levofloxacin: case presentation and literature review. <i>Eur J Clin Pharmacol</i>. 2009;65(10):959‐962. doi:10.1007/s00228-009-0717-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/19707748/pubmed" id="19707748" target="_blank">19707748</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26316526">
<a name="26316526"></a>Berbari EF, Kanj SS, Kowalski TJ, et al. Executive summary: 2015 Infectious Diseases Society of America (IDSA) clinical practice guidelines for the diagnosis and treatment of native vertebral osteomyelitis in adults. <i>Clin Infect Dis</i>. 2015;61(6):859-863. doi: 10.1093/cid/civ633.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/26316526/pubmed" id="26316526" target="_blank">26316526</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28467526">
<a name="28467526"></a>Berríos-Torres SI, Umscheid CA, Bratzler DW, et al; Healthcare Infection Control Practices Advisory Committee. Centers for Disease Control and Prevention guideline for the prevention of surgical site infection, 2017. <i>JAMA Surg.</i> 2017;152(8):784-791. doi: 10.1001/jamasurg.2017.0904.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/28467526/pubmed" id="28467526" target="_blank">28467526</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32365216">
<a name="32365216"></a>Betschart C, Albrich WC, Brandner S, et al. Guideline of the Swiss Society of Gynaecology and Obstetrics (SSGO) on acute and recurrent urinary tract infections in women, including pregnancy. <i>Swiss Med Wkly</i>. 2020;150:w20236. doi: 10.4414/smw.2020.20236<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/32365216/pubmed" id="32365216" target="_blank">32365216</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26926640">
<a name="26926640"></a>Bidell MR, Palchak M, Mohr J, Lodise TP. Fluoroquinolone and third-generation-cephalosporin resistance among hospitalized patients with urinary tract infections due to Escherichia coli: do rates vary by hospital characteristics and geographic region? <i>Antimicrob Agents Chemother.</i> 2016a;60(5):3170-3173. doi:10.1128/AAC.02505-15<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/26926640/pubmed" id="26926640" target="_blank">26926640</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27138564">
<a name="27138564"></a>Bidell MR, Lodise TP. Fluoroquinolone-associated tendinopathy: does levofloxacin pose the greatest risk?. <i>Pharmacotherapy</i>. 2016b;36(6):679‐693. doi:10.1002/phar.1761<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/27138564/pubmed" id="27138564" target="_blank">27138564</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29441476">
<a name="29441476"></a>Bilbao-Meseguer I, Rodríguez-Gascón A, Barrasa H, Isla A, Solinís MÁ. Augmented renal clearance in critically ill patients: a systematic review. <i>Clin Pharmacokinet</i>. 2018;57(9):1107-1121. doi:10.1007/s40262-018-0636-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/29441476/pubmed" id="29441476" target="_blank">29441476</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30811525">
<a name="30811525"></a>Bisaccia DR, Aicale R, Tarantino D, Peretti GM, Maffulli N. Biological and chemical changes in fluoroquinolone-associated tendinopathies: a systematic review. <i>Br Med Bull</i>. 2019;130(1):39‐49. doi:10.1093/bmb/ldz006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/30811525/pubmed" id="30811525" target="_blank">30811525</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31834290">
<a name="31834290"></a>Bower WA, Schiffer J, Atmar RL, et al; CDC ACIP Anthrax Vaccine Work Group. Use of anthrax vaccine in the United States: recommendations of the Advisory Committee on Immunization Practices, 2019. <i>MMWR Recomm Rep</i>. 2019;68(4):1-14. doi:10.15585/mmwr.rr6804a1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/31834290/pubmed" id="31834290" target="_blank">31834290</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21880587">
<a name="21880587"></a>Bradley JS, Byington CL, Shah SS, et al. “The Management of Community-Acquired Pneumonia in Infants and Children Older Than 3 Months of Age: Clinical Practice Guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America”, <i>Clin Infect Dis</i>, 2011, 53(7):e25-76.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/21880587/pubmed" id="21880587" target="_blank">21880587</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24918220">
<a name="24918220"></a>Bradley JS, Kauffman RE, Balis DA, et al. Assessment of musculoskeletal toxicity 5 years after therapy with levofloxacin. <i>Pediatrics</i>. 2014;134(1):e146-e153. doi:10.1542/peds.2013-3636<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/24918220/pubmed" id="24918220" target="_blank">24918220</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Bradley.1">
<a name="Bradley.1"></a>Bradley JS, Nelson JD, Kimberlin DK, et al, eds. <i>Nelson's Pocket Book of Pediatric Antimicrobial Therapy</i>. 28th ed. American Academy of Pediatrics; 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24777226">
<a name="24777226"></a>Bradley JS, Peacock G, Krug SE; AAP Committee on Infectious Diseases and Disaster Preparedness Advisory Council. Pediatric anthrax clinical management. <i>Pediatrics</i>. 2014;133(5):e1411-e1436. doi:10.1542/peds.2014-0563.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/24777226/pubmed" id="24777226" target="_blank">24777226</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23461695">
<a name="23461695"></a>Bratzler DW, Dellinger EP, Olsen KM, et al, "Clinical Practice Guidelines for Antimicrobial Prophylaxis in Surgery," <i>Surg Infect (Larchmt)</i>, 2013, 14(1):73-156.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/23461695/pubmed" id="23461695" target="_blank">23461695</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23327981">
<a name="23327981"></a>Bratzler DW, Dellinger EP, Olsen KM, et al; American Society of Health-System Pharmacists; Infectious Diseases Society of America; Surgical Infection Society; Society for Healthcare Epidemiology of America. Clinical practice guidelines for antimicrobial prophylaxis in surgery. <i>Am J Health Syst Pharm.</i> 2013;70(3):195-283.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/23327981/pubmed" id="23327981" target="_blank">23327981</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23478961">
<a name="23478961"></a>Brown KA, Khanafer N, Daneman N, Fisman DN. Meta-analysis of antibiotics and the risk of community-associated <i>Clostridium difficile</i> infection. <i>Antimicrob Agents Chemother</i>. 2013;57(5):2326‐2332. doi:10.1128/AAC.02176-12<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/23478961/pubmed" id="23478961" target="_blank">23478961</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16148283">
<a name="16148283"></a>Bucaneve G, Micozzi A, Menichetti F, et al; Gruppo Italiano Malattie Ematologiche dell’Adulto (GIMEMA) Infection Program. Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. <i>N Engl J Med</i>. 2005;353(10):977-987.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/16148283/pubmed" id="16148283" target="_blank">16148283</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15767227">
<a name="15767227"></a>Cahill JB Jr, Bailey EM, Chien S, et al, "Levofloxacin Secretion in Breast Milk: A Case Report," <i>Pharmacotherapy</i>, 2005, 25(1):116-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/15767227/pubmed" id="15767227" target="_blank">15767227</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21160459">
<a name="21160459"></a>Centers for Disease Control and Prevention (CDC), "Sexually Transmitted Diseases Treatment Guidelines, 2010," <i>MMWR Recomm Rep</i>, 2010, 59(RR-12):1-110.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/21160459/pubmed" id="21160459" target="_blank">21160459</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6810084">
<a name="6810084"></a>Centers for Disease Control and Prevention. Neonatal deaths associated with use of benzyl alcohol—United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a>
<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/6810084/pubmed" id="6810084" target="_blank">6810084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12836625">
<a name="12836625"></a>Centers for Disease Control and Prevention. Treatment of tuberculosis. American Thoracic Society, CDC, and Infectious Diseases Society of America [published correction appears in <i>MMWR Recomm Rep</i>. 2005;53(51):1203]. <i>MMWR Recomm Rep.</i> 2003;52(RR-11):1-77. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/rr5211a1.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5211a1.htm</a>.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/12836625/pubmed" id="12836625" target="_blank">12836625</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-CDC.2015">
<a name="CDC.2015"></a>Centers for Disease Control and Prevention. Plague: Resources for clinicians. <a href="https://www.cdc.gov/plague/healthcare/clinicians.html" target="_blank">https://www.cdc.gov/plague/healthcare/clinicians.html</a>. Updated October 5, 2015. Accessed September 12, 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-CDC..2017">
<a name="CDC..2017"></a>Centers for Disease Control and Prevention. The pre-travel consultation: travelers' diarrhea. The Yellow Book: CDC health information for international travel, 2018. <a href="https://wwwnc.cdc.gov/travel/yellowbook/2018/the-pre-travel-consultation/travelers-diarrhea" target="_blank">https://wwwnc.cdc.gov/travel/yellowbook/2018/the-pre-travel-consultation/travelers-diarrhea</a>. Updated June 13, 2017. Accessed September 6, 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-CDC.2020">
<a name="CDC.2020"></a>Centers for Disease Control and Prevention (CDC). FAQs for clinicians about <i>C. diff</i>. <a href="https://www.cdc.gov/cdiff/clinicians/faq.html" target="_blank">https://www.cdc.gov/cdiff/clinicians/faq.html</a>. March 27, 2020. Accessed May 6, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24935270">
<a name="24935270"></a>Chalasani NP, Hayashi PH, Bonkovsky HL, et al. ACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury. <i>Am J Gastroenterol</i>. 2014;109(7):950‐967. doi:10.1038/ajg.2014.131<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/24935270/pubmed" id="24935270" target="_blank">24935270</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26238129">
<a name="26238129"></a>Charfi O, Lakhoua G, Sahnoun R, et al. DRESS syndrome following levofloxacin exposure with positive patch-test. <i>Therapie</i>. 2015;70(6):547‐549. doi:10.2515/therapie/2015046<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/26238129/pubmed" id="26238129" target="_blank">26238129</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28071659">
<a name="28071659"></a>Chey WD, Leontiadis GI, Howden CW, Moss SF. ACG clinical guideline: treatment of <i>Helicobacter pylori</i> infection. <i>Am J Gastroenterol</i>. 2017;112(2):212-239. doi: 10.1038/ajg.2016.563<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/28071659/pubmed" id="28071659" target="_blank">28071659</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17608775">
<a name="17608775"></a>Chey WD, Wong B. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. <i>Am J Gastroenterol</i>. 2007;102(8):1808-1825.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/17608775/pubmed" id="17608775" target="_blank">17608775</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15647407">
<a name="15647407"></a>Chien S, Wells TG, Blumer JL, et al. Levofloxacin pharmacokinetics in children. <i>J Clin Pharmacol</i>. 2005;45(2):153-160.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/15647407/pubmed" id="15647407" target="_blank">15647407</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25102221">
<a name="25102221"></a>Chmiel JF, Aksamit TR, Chotirmall SH, et al. Antibiotic management of lung infections in cystic fibrosis. I. The microbiome, methicillin-resistant Staphylococcus aureus, gram-negative bacteria, and multiple infections. <i>Ann Am Thorac Soc</i>. 2014;11(7):1120-1129.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/25102221/pubmed" id="25102221" target="_blank">25102221</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23948133">
<a name="23948133"></a>Chou HW, Wang JL, Chang CH, Lee JJ, Shau WY, Lai MS. Risk of severe dysglycemia among diabetic patients receiving levofloxacin, ciprofloxacin, or moxifloxacin in Taiwan. <i>Clin Infect Dis</i>. 2013;57(7):971‐980. doi:10.1093/cid/cit439<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/23948133/pubmed" id="23948133" target="_blank">23948133</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Chow.1">
<a name="Chow.1"></a>Chow AW. Complications, diagnosis, and treatment of odontogenic infections. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed August 9, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22438350">
<a name="22438350"></a>Chow AW, Benninger MS, Brook I, et al; Infectious Diseases Society of America. IDSA clinical practice guideline for acute bacterial rhinosinusitis in children and adults. <i>Clin Infect Dis.</i> 2012; 54(8):e72-e112.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/22438350/pubmed" id="22438350" target="_blank">22438350</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11793615">
<a name="11793615"></a>Cohen JS. Peripheral neuropathy associated with fluoroquinolones. <i>Ann Pharmacother</i>. 2001;35(12):1540‐1547. doi:10.1345/aph.1Z429<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/11793615/pubmed" id="11793615" target="_blank">11793615</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28031199">
<a name="28031199"></a>Cojutti PG, Ramos-Martin V, Schiavon I, et al. Population pharmacokinetics and pharmacodynamics of levofloxacin in acutely hospitalized older patients with various degrees of renal function. <i>Antimicrob Agents Chemother</i>. 2017;61(3):e02134-16. doi:10.1128/AAC.02134-16<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/28031199/pubmed" id="28031199" target="_blank">28031199</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24755188">
<a name="24755188"></a>Collins CE, Ayturk MD, Flahive JM, Emhoff TA, Anderson FA Jr, Santry HP. Epidemiology and outcomes of community-acquired <i>Clostridium difficile</i> infections in Medicare beneficiaries. <i>J Am Coll Surg</i>. 2014;218(6):1141‐1147.e1. doi:10.1016/j.jamcollsurg.2014.01.053<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/24755188/pubmed" id="24755188" target="_blank">24755188</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30261569">
<a name="30261569"></a>Connors TM, Restrepo A, Dao H Jr. Brown-gray hyperpigmentation in a photosensitive distribution after levofloxacin exposure. <i>Dermatol Online J</i>. 2018;24(7):13030/qt5t72v66n.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/30261569/pubmed" id="30261569" target="_blank">30261569</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16148284">
<a name="16148284"></a>Cullen M, Steven N, Billingham L, et al; Simple Investigation in Neutropenic Individuals of the Frequency of Infection after Chemotherapy +/- Antibiotic in a Number of Tumours (SIGNIFICANT) Trial Group. Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas. <i>N Engl J Med</i>. 2005;353(10):988-998.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/16148284/pubmed" id="16148284" target="_blank">16148284</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17699357">
<a name="17699357"></a>Czock D, Hüsig-Linde C, Langhoff A, et al. Pharmacokinetics of moxifloxacin and levofloxacin in intensive care unit patients who have acute renal failure and undergo extended daily dialysis. <i>Clin J Am Soc Nephrol</i>. 2006;1(6):1263-1268.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/17699357/pubmed" id="17699357" target="_blank">17699357</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19492670">
<a name="19492670"></a>Davila G, Ruiz-Hornillos J, Rojas P, De Castro F, Zubeldia JM. Toxic epidermal necrolysis induced by levofloxacin. <i>Ann Allergy Asthma Immunol</i>. 2009;102(5):441‐442. doi:10.1016/S1081-1206(10)60521-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/19492670/pubmed" id="19492670" target="_blank">19492670</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36669519">
<a name="36669519"></a>de Wijkerslooth EML, Boerma EG, van Rossem CC, et al; APPIC Study Group. 2 days versus 5 days of postoperative antibiotics for complex appendicitis: a pragmatic, open-label, multicentre, non-inferiority randomised trial.<i> Lancet</i>. 2023;401(10374):366-376. doi:10.1016/S0140-6736(22)02588-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/36669519/pubmed" id="36669519" target="_blank">36669519</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30664553">
<a name="30664553"></a>Desai M, Fathallah J, Nutalapati V, Saligram S. Antibiotics versus no antibiotics for acute uncomplicated diverticulitis: a systematic review and meta-analysis. <i>Dis Colon Rectum</i>. 2019;62(8):1005-1012. doi:10.1097/DCR.0000000000001324<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/30664553/pubmed" id="30664553" target="_blank">30664553</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23620467">
<a name="23620467"></a>Deshpande A, Pasupuleti V, Thota P, et al. Community-associated <i>Clostridium difficile</i> infection and antibiotics: a meta-analysis. <i>J Antimicrob Chemother</i>. 2013;68(9):1951‐1961. doi:10.1093/jac/dkt129<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/23620467/pubmed" id="23620467" target="_blank">23620467</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30496461">
<a name="30496461"></a>Deshpande D, Pasipanodya JG, Mpagama SG, et al. Levofloxacin pharmacokinetics/pharmacodynamics, dosing, susceptibility breakpoints, and artificial intelligence in the treatment of multidrug-resistant tuberculosis. <i>Clin Infect Dis</i>. 2018;67(suppl_3):S293-S302. doi:10.1093/cid/ciy611<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/30496461/pubmed" id="30496461" target="_blank">30496461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15116294">
<a name="15116294"></a>Drusano GL, Preston SL, Fowler C, Corrado M, Weisinger B, Kahn J. Relationship between fluoroquinolone area under the curve: minimum inhibitory concentration ratio and the probability of eradication of the infecting pathogen, in patients with nosocomial pneumonia. <i>J Infect Dis.</i> 2004;189(9):1590-1597. doi:10.1086/383320<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/15116294/pubmed" id="15116294" target="_blank">15116294</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9397218">
<a name="9397218"></a>Ernst ME, Ernst EJ, and Klepser ME, “Levofloxacin and Trovafloxacin: The Next Generation of Fluoroquinolones?” <i>Am J Health Syst Pharm</i>, 1997, 54(22):2569-84.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/9397218/pubmed" id="9397218" target="_blank">9397218</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29997980">
<a name="29997980"></a>Esmail A, Sabur NF, Okpechi I, Dheda K. Management of drug-resistant tuberculosis in special sub-populations including those with HIV co-infection, pregnancy, diabetes, organ-specific dysfunction, and in the critically ill. <i>J Thorac Dis</i>. 2018;10(5):3102-3118. doi: 10.21037/jtd.2018.05.11<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/29997980/pubmed" id="29997980" target="_blank">29997980</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29511692">
<a name="29511692"></a>Estofan LJF, Naydin S, Gliebus G. Quinolone-induced painful peripheral neuropathy: a case report and literature review. <i>J Investig Med High Impact Case Rep</i>. 2018;6:2324709617752736. doi:10.1177/2324709617752736<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/29511692/pubmed" id="29511692" target="_blank">29511692</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOO">
<a name="Expert.DOO"></a>Expert opinion. Senior Obesity Editorial Team: Jeffrey F. Barletta, PharmD, FCCM; Manjunath P. Pai, PharmD, FCP; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Eyre.1">
<a name="Eyre.1"></a>Eyre RC. Evaluation of acute scrotal pain in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed October 12, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-File.1">
<a name="File.1"></a>File TM. Treatment of community-acquired pneumonia in adults in the outpatient setting. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed January 4, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-FDA.2018">
<a name="FDA.2018"></a>Food and Drug Administration (FDA). FDA drug safety communication: FDA warns about increased risk of ruptures or tears in the aorta blood vessel with fluoroquinolone antibiotics in certain patients. <a href="https://www.fda.gov/Drugs/DrugSafety/ucm628753.htm" target="_blank">https://www.fda.gov/Drugs/DrugSafety/ucm628753.htm</a>. Published December 20, 2018. Accessed January 22, 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26425618">
<a name="26425618"></a>Francis JK, Higgins E. Permanent peripheral neuropathy: a case report on a rare but serious debilitating side-effect of fluoroquinolone administration. <i>J Investig Med High Impact Case Rep</i>. 2014;2(3):2324709614545225. doi:10.1177/2324709614545225<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/26425618/pubmed" id="26425618" target="_blank">26425618</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21258094">
<a name="21258094"></a>Freifeld AG, Bow EJ, Sepkowitz KA, et al; Infectious Diseases Society of America. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. <i>Clin Infect Dis</i>. 2011;52(4):e56-e93.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/21258094/pubmed" id="21258094" target="_blank">21258094</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16206101">
<a name="16206101"></a>Frothingham R, “Glucose Homeostasis Abnormalities Associated With Use of Gatifloxacin,” <i>Clin Infect Dis</i>, 2005, 41(9):1269-76.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/16206101/pubmed" id="16206101" target="_blank">16206101</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1503449">
<a name="1503449"></a>Fu KP, Lafredo SC, Foleno B, et al. In vitro and in vivo antibacterial activities of levofloxacin (l-ofloxacin), an optically active ofloxacin. <i>Antimicrob Agents Chemother.</i> 1992;36(4):860-866. doi:10.1128/aac.36.4.860<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/1503449/pubmed" id="1503449" target="_blank">1503449</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12917240">
<a name="12917240"></a>Garrison MW. Comparative antimicrobial activity of levofloxacin and ciprofloxacin against Streptococcus pneumoniae. <i>J Antimicrob Chemother.</i> 2003;52(3):503-506. doi:10.1093/jac/dkg380<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/12917240/pubmed" id="12917240" target="_blank">12917240</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19022360">
<a name="19022360"></a>Ge DT, Law PY, Kong SK, Ho YY. Disturbance of cellular glucose transport by two prevalently used fluoroquinolone antibiotics ciprofloxacin and levofloxacin involves glucose transporter type 1. <i>Toxicol Lett</i>. 2009;184(2):81‐84. doi:10.1016/j.toxlet.2008.10.017<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/19022360/pubmed" id="19022360" target="_blank">19022360</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19073153">
<a name="19073153"></a>Ghaly H, Kriete C, Sahin S, et al. The insulinotropic effect of fluoroquinolones. <i>Biochem Pharmacol</i>. 2009;77(6):1040‐1052. doi:10.1016/j.bcp.2008.11.019<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/19073153/pubmed" id="19073153" target="_blank">19073153</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24284031">
<a name="24284031"></a>Ghaly H, Jörns A, Rustenbeck I. Effect of fluoroquinolones on mitochondrial function in pancreatic beta cells. <i>Eur J Pharm Sci</i>. 2014;52:206‐214. doi:10.1016/j.ejps.2013.11.011<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/24284031/pubmed" id="24284031" target="_blank">24284031</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-GOLD.1">
<a name="GOLD.1"></a>Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for prevention, diagnosis and management of COPD: 2023 report. https://goldcopd.org/2023-gold-report-2/. Updated 2023. Accessed January 30, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30368737">
<a name="30368737"></a>Gorelik E, Masarwa R, Perlman A, et al. Fluoroquinolones and cardiovascular risk: a systematic review, meta-analysis and network meta-analysis. <i>Drug Saf</i>. 2019;42(4):529‐538. doi:10.1007/s40264-018-0751-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/30368737/pubmed" id="30368737" target="_blank">30368737</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12145720">
<a name="12145720"></a>Graham DR, Talan DA, Nichols RL, et al. Once-daily, high-dose levofloxacin versus ticarcillin-clavulanate alone or followed by amoxicillin-clavulanate for complicated skin and skin-structure infections: a randomized, open-label trial. <i>Clin Infect Dis</i>. 2002;35(4):381-389.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/12145720/pubmed" id="12145720" target="_blank">12145720</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16641428">
<a name="16641428"></a>Griffith DC, Corcoran E, Lofland D, et al. Pharmacodynamics of levofloxacin against Pseudomonas aeruginosa with reduced susceptibility due to different efflux pumps: do elevated MICs always predict reduced in vivo efficacy? <i>Antimicrob Agents Chemother.</i> 2006;50(5):1628-1632. doi:10.1128/AAC.50.5.1628-1632.2006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/16641428/pubmed" id="16641428" target="_blank">16641428</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24067876">
<a name="24067876"></a>Gulen M, Ay MO, Avci A, Acikalin A, Icme F. Levofloxacin-induced hepatotoxicity and death. <i>Am J Ther</i>. 2015;22(3):e93‐e96. doi:10.1097/MJT.0b013e3182a44055<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/24067876/pubmed" id="24067876" target="_blank">24067876</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hooton.2021c">
<a name="Hooton.2021c"></a>Gupta K. Acute complicated urinary tract infection (including pyelonephritis) in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 20, 2021c.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hooton.2021a">
<a name="Hooton.2021a"></a>Gupta K. Acute simple cystitis in females. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 16, 2021a.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hooton.2021b">
<a name="Hooton.2021b"></a>Gupta K. Acute simple cystitis in adult males. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 11, 2021b.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21292654">
<a name="21292654"></a>Gupta K, Hooton TM, Naber KG, et al; Infectious Diseases Society of America; European Society for Microbiology and Infectious Diseases. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. <i>Clin Infect Dis</i>. 2011;52(5):e103-e120. doi:10.1093/cid/ciq257<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/21292654/pubmed" id="21292654" target="_blank">21292654</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26112269">
<a name="26112269"></a>Hall RG 2nd. Evolving larger: dosing anti-tuberculosis (TB) drugs in an obese world. <i>Curr Pharm Des</i>. 2015;21(32):4748-4751. doi:10.2174/1381612821666150625120936<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/26112269/pubmed" id="26112269" target="_blank">26112269</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8390432">
<a name="8390432"></a>Halliwell RF, Davey PG, Lambert JJ. Antagonism of GABAA receptors by 4-quinolones. <i>J Antimicrob Chemother</i>. 1993;31(4):457‐462. doi:10.1093/jac/31.4.457<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/8390432/pubmed" id="8390432" target="_blank">8390432</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11396281">
<a name="11396281"></a>Hansen E, Bucher M, Jakob W, Lemberger P, Kees F. Pharmacokinetics of levofloxacin during continuous veno-venous hemofiltration. <i>Intensive Care Med</i>. 2001;27(2):371-375.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/11396281/pubmed" id="11396281" target="_blank">11396281</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26785402">
<a name="26785402"></a>Harris AM, Hicks LA, Qaseem A; High Value Care Task Force of the American College of Physicians and for the Centers for Disease Control and Prevention. Appropriate antibiotic use for acute respiratory tract infection in adults: advice for high-value care from the American College of Physicians and the Centers for Disease Control and Prevention. <i>Ann Intern Med.</i> 2016;164(6):425-434. doi: 10.7326/M15-1840.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/26785402/pubmed" id="26785402" target="_blank">26785402</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17950810">
<a name="17950810"></a>Hatzaras IS, Bible JE, Koullias GJ, Tranquilli M, Singh M, Elefteriades JA. Role of exertion or emotion as inciting events for acute aortic dissection. <i>Am J Cardiol</i>. 2007;100(9):1470‐1472. doi:10.1016/j.amjcard.2007.06.039<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/17950810/pubmed" id="17950810" target="_blank">17950810</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19397464">
<a name="19397464"></a>Heintz BH, Matzke GR, Dager WE. Antimicrobial dosing concepts and recommendations for critically ill adult patients receiving continuous renal replacement therapy or intermittent hemodialysis. <i>Pharmacotherapy.</i> 2009;29(5):562-577.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/19397464/pubmed" id="19397464" target="_blank">19397464</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24447897">
<a name="24447897"></a>Hendricks KA, Wright ME, Shadomy SV, et al; Workgroup on Anthrax Clinical Guidelines. Centers for Disease Control and Prevention expert panel meetings on prevention and treatment of anthrax in adults. <i>Emerg Infect Dis.</i> 2014;20(2):e130687. doi:10.3201/eid2002.130687<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/24447897/pubmed" id="24447897" target="_blank">24447897</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22146873">
<a name="22146873"></a>Hensgens MP, Goorhuis A, Dekkers OM, Kuijper EJ. Time interval of increased risk for <i>Clostridium difficile</i> infection after exposure to antibiotics. <i>J Antimicrob Chemother</i>. 2012;67(3):742‐748. doi:10.1093/jac/dkr508<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/22146873/pubmed" id="22146873" target="_blank">22146873</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19072244">
<a name="19072244"></a>High KP, Bradley SF, Gravenstein S, et al. Clinical practice guideline for the evaluation of fever and infection in older adult residents of long-term care facilities: 2008 update by the Infectious Diseases Society of America. <i>Clin Infect Dis</i>. 2009;48(2):149-171.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/19072244/pubmed" id="19072244" target="_blank">19072244</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31342772">
<a name="31342772"></a>Hoff BM, Maker JH, Dager WE, Heintz BH. Antibiotic dosing for critically ill adult patients receiving intermittent hemodialysis, prolonged intermittent renal replacement therapy, and continuous renal replacement therapy: an update. <i>Ann Pharmacother</i>. 2020;54(1):43-55. doi:10.1177/1060028019865873<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/31342772/pubmed" id="31342772" target="_blank">31342772</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hohmann.2020b">
<a name="Hohmann.2020b"></a>Hohmann EL. Nontyphoidal Salmonella bacteremia. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed January 15, 2020b.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hohmann.2020a">
<a name="Hohmann.2020a"></a>Hohmann EL. Nontyphoidal Salmonella: Gastrointestinal infection and carriage. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed June 27, 2022a.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8026158">
<a name="8026158"></a>Houston AK, Jones RN. Postantibiotic effect of DU-6859a and levofloxacin as compared with ofloxacin. <i>Diagn Microbiol Infect Dis.</i> 1994;18(1):57-59. doi:10.1016/0732-8893(94)90134-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/8026158/pubmed" id="8026158" target="_blank">8026158</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hsu.1">
<a name="Hsu.1"></a>Hsu K. Treatment of Chlamydia trachomatis infection. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed August 10, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32004540">
<a name="32004540"></a>Iguchi T, Goto K, Watanabe K, et al. Fluoroquinolones suppress gluconeogenesis by inhibiting fructose 1,6-bisphosphatase in primary monkey hepatocytes. <i>Toxicol In Vitro</i>. 2020;65:104786. doi:10.1016/j.tiv.2020.104786<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/32004540/pubmed" id="32004540" target="_blank">32004540</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25902267">
<a name="25902267"></a>Ilgin S, Can OD, Atli O, Ucel UI, Sener E, Guven I. Ciprofloxacin-induced neurotoxicity: evaluation of possible underlying mechanisms. <i>Toxicol Mech Methods</i>. 2015;25(5):374‐381. doi:10.3109/15376516.2015.1026008<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/25902267/pubmed" id="25902267" target="_blank">25902267</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9024461">
<a name="9024461"></a>"Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/9024461/pubmed" id="9024461" target="_blank">9024461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15886293">
<a name="15886293"></a>Islam AF, Rahman MS. Levofloxacin-induced fatal toxic epidermal necrolysis. <i>Ann Pharmacother</i>. 2005;39(6):1136‐1137. doi:10.1345/aph.1E613<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/15886293/pubmed" id="15886293" target="_blank">15886293</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10891521">
<a name="10891521"></a>Ito S. Drug therapy for breast-feeding women. <i>N Engl J Med</i>. 2000;343(2):118-126.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/10891521/pubmed" id="10891521" target="_blank">10891521</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27940800">
<a name="27940800"></a>Jackson MA, Schutze GE, Committee on Infectious Diseases. The use of systemic and topical fluoroquinolones. <i>Pediatrics</i>. 2016;138(5):e20162706. doi:10.1542/peds.2016-2706<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/27940800/pubmed" id="27940800" target="_blank">27940800</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21879778">
<a name="21879778"></a>Jones SC, Sorbello A, Boucher RM. Fluoroquinolone-associated myasthenia gravis exacerbation: evaluation of postmarketing reports from the US FDA adverse event reporting system and a literature review. <i>Drug Saf</i>. 2011;34(10):839‐847. doi:10.2165/11593110-000000000-00000<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/21879778/pubmed" id="21879778" target="_blank">21879778</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23825301">
<a name="23825301"></a>Kalghatgi S, Spina CS, Costello JC, et al. Bactericidal antibiotics induce mitochondrial dysfunction and oxidative damage in Mammalian cells. <i>Sci Transl Med</i>. 2013;5(192):192ra85. doi:10.1126/scitranslmed.3006055<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/23825301/pubmed" id="23825301" target="_blank">23825301</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27418577">
<a name="27418577"></a>Kalil AC, Metersky ML, Klompas M, et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society. <i>Clin Infect Dis</i>. 2016;63(5):e61-e111. doi:10.1093/cid/ciw353<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/27418577/pubmed" id="27418577" target="_blank">27418577</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Kanamore.1">
<a name="Kanamore.1"></a>Kanamore M, Mihara K, Hanada K, et al. Peritoneal clearance and optimum dosage regimen of levofloxacin in patients under continuous ambulatory peritoneal dialysis. <i>Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics.</i> 2001;32(3):91-99. doi:10.3999/jscpt.32.3_91</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11125032">
<a name="11125032"></a>Kang J, Wang L, Chen XL, Triggle DJ, Rampe D. Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG. <i>Mol Pharmacol</i>. 2001;59(1):122‐126. doi:10.1124/mol.59.1.122<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/11125032/pubmed" id="11125032" target="_blank">11125032</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26052598">
<a name="26052598"></a>Kaplan YC, Koren G. Use of ciprofloxacin during breastfeeding. <i>Can Fam Physician</i>. 2015;61(4):343-344.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/26052598/pubmed" id="26052598" target="_blank">26052598</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30003982">
<a name="30003982"></a>Kim WB, Shelley AJ, Novice K, Joo J, Lim HW, Glassman SJ. Drug-induced phototoxicity: A systematic review. <i>J Am Acad Dermatol</i>. 2018;79(6):1069‐1075. doi:10.1016/j.jaad.2018.06.061<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/30003982/pubmed" id="30003982" target="_blank">30003982</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9536423">
<a name="9536423"></a>Kimura M, Kawada A. Photosensitivity induced by lomefloxacin with cross-photosensitivity to ciprofloxacin and fleroxacin. <i>Contact Dermatitis</i>. 1998;38(3):180. doi:10.1111/j.1600-0536.1998.tb05698.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/9536423/pubmed" id="9536423" target="_blank">9536423</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30448331">
<a name="30448331"></a>Ko JH, Kang CI, Cornejo-Juárez P, et al. Fluoroquinolones versus trimethoprim-sulfamethoxazole for the treatment of Stenotrophomonas maltophilia infections: a systematic review and meta-analysis. <i>Clin Microbiol Infect.</i> 2019;25(5):546-554. doi:10.1016/j.cmi.2018.11.008<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/30448331/pubmed" id="30448331" target="_blank">30448331</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10049286">
<a name="10049286"></a>Lacy MK, Lu W, Xu X, et al. Pharmacodynamic comparisons of levofloxacin, ciprofloxacin, and ampicillin against Streptococcus pneumoniae in an in vitro model of infection. <i>Antimicrob Agents Chemother.</i> 1999;43(3):672-677. doi:10.1128/AAC.43.3.672<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/10049286/pubmed" id="10049286" target="_blank">10049286</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30213330">
<a name="30213330"></a>Lee CC, Lee MG, Hsieh R, et al. Oral fluoroquinolone and the risk of aortic dissection. <i>J Am Coll Cardiol</i>. 2018a;72(12):1369-1378. doi: 10.1016/j.jacc.2018.06.067.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/30213330/pubmed" id="30213330" target="_blank">30213330</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23450078">
<a name="23450078"></a>Lee JH, Lee WY, Yong SJ, et al. A case of levofloxacin-induced anaphylaxis with elevated serum tryptase levels. <i>Allergy Asthma Immunol Res</i>. 2013;5(2):113‐115. doi:10.4168/aair.2013.5.2.113<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/23450078/pubmed" id="23450078" target="_blank">23450078</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29170868">
<a name="29170868"></a>Lee SSF, Fulford AE, Quinn MA, Seabrook J, Rajakumar I. Levofloxacin for febrile neutropenia prophylaxis in acute myeloid leukemia patients associated with reduction in hospital admissions.<i> Support Care Cancer.</i> 2018b;26(5):1499-1504. doi: 10.1007/s00520-017-3976-1.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/29170868/pubmed" id="29170868" target="_blank">29170868</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31676904">
<a name="31676904"></a>Lehrnbecher T, Fisher BT, Phillips B, et al. Guideline for antibacterial prophylaxis administration in pediatric cancer and hematopoietic stem cell transplantation. <i>Clin Infect Dis</i>. 2020;71(1):226-236. doi:10.1093/cid/ciz1082<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/31676904/pubmed" id="31676904" target="_blank">31676904</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Levaquin (levofloxacin) [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals Inc; May 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24879988">
<a name="24879988"></a>Levine C, Trivedi A, Thung SN, Perumalswami PV. Severe ductopenia and cholestasis from levofloxacin drug-induced liver injury: a case report and review. <i>Semin Liver Dis</i>. 2014;34(2):246‐251. doi:10.1055/s-0034-1375964<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/24879988/pubmed" id="24879988" target="_blank">24879988</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Levofloxacin injection [prescribing information]. E. Windsor, NJ: AuroMedics Pharma LLC; November 2021.</div>
</li>
<li>
<div class="reference">
                  Levofloxacin injection in 5% Dextrose [prescribing information]. Paramus, NJ: WG Critical Care, LLC; March 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Levofloxacin.3">
<a name="Levofloxacin.3"></a>Levofloxacin oral solution [prescribing information]. Gurnee, IL: Akorn Operating Company LLC; November 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Levofloxacin.4">
<a name="Levofloxacin.4"></a>Levofloxacin tablets [prescribing information]. Princeton, NJ: Macleods Pharma USA Inc; February 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Levofloxacin.5">
<a name="Levofloxacin.5"></a>Levofloxacin in 5% Dextrose Injection [product monograph]. Kirkland, Quebec, Canada: Pfizer Canada ULC; August 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9145850">
<a name="9145850"></a>Licata L, Smith CE, Goldschmidt RM, Barrett JF, Frosco M. Comparison of the postantibiotic and postantibiotic sub-MIC effects of levofloxacin and ciprofloxacin on Staphylococcus aureus and Streptococcus pneumoniae. <i>Antimicrob Agents Chemother. </i>1997;41(5):950-955. doi:10.1128/AAC.41.5.950<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/9145850/pubmed" id="9145850" target="_blank">9145850</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23439909">
<a name="23439909"></a>Lieberthal AS, Carroll AE, Chonmaitree T, et al. The diagnosis and management of acute otitis media. <i>Pediatrics</i>. 2013;131(3):e964-e999. doi:10.1542/peds.2012-3488<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/23439909/pubmed" id="23439909" target="_blank">23439909</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20459324">
<a name="20459324"></a>Lipsky BA, Byren I, Hoey CT. Treatment of bacterial prostatitis. <i>Clin Infect Dis.</i> 2010;50(12):1641-1652. doi: 10.1086/652861.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/20459324/pubmed" id="20459324" target="_blank">20459324</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22619242">
<a name="22619242"></a>Lipsky BA, Berendt AR, Cornia PB, et al; Infectious Diseases Society of America. 2012 Infectious Diseases Society of America clinical practice guideline for the diagnosis and treatment of diabetic foot infections. <i>Clin Infect Dis.</i> 2012;54(12):e132-e173.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/22619242/pubmed" id="22619242" target="_blank">22619242</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10381104">
<a name="10381104"></a>Lister PD, Sanders CC. Pharmacodynamics of levofloxacin and ciprofloxacin against Streptococcus pneumoniae. <i>J Antimicrob Chemother</i>. 1999;43(1):79-86. doi:10.1093/jac/43.1.79<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/10381104/pubmed" id="10381104" target="_blank">10381104</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20397737">
<a name="20397737"></a>Liu HH. Safety profile of the fluoroquinolones: focus on levofloxacin. <i>Drug Saf</i>. 2010;33(5):353‐369. doi:10.2165/11536360-000000000-00000<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/20397737/pubmed" id="20397737" target="_blank">20397737</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30856392">
<a name="30856392"></a>Liu R, Hu S, Zhang Y, et al. Mast cell-mediated hypersensitivity to fluoroquinolone is MRGPRX2 dependent. <i>Int Immunopharmacol</i>. 2019;70:417‐427. doi:10.1016/j.intimp.2019.02.001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/30856392/pubmed" id="30856392" target="_blank">30856392</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21474480">
<a name="21474480"></a>Luque S, Grau S, Valle M, Colino CI, Ferrer A. Levofloxacin weight-adjusted dosing and pharmacokinetic disposition in a morbidly obese patient. <i>J Antimicrob Chemother</i>. 2011;66(7):1653-1654. doi:10.1093/jac/dkr146<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/21474480/pubmed" id="21474480" target="_blank">21474480</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32702756">
<a name="32702756"></a>Luzzatto L, Ally M, Notaro R. Glucose-6-phosphate dehydrogenase deficiency. <i>Blood</i>. 2020;136(11):1225-1240. doi:10.1182/blood.2019000944<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/32702756/pubmed" id="32702756" target="_blank">32702756</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22900968">
<a name="22900968"></a>Ma HJ, Hu R, Jia CY, Yang Y, Song LJ. Case of drug-induced bullous pemphigoid by levofloxacin. <i>J Dermatol</i>. 2012;39(12):1086‐1087. doi:10.1111/j.1346-8138.2012.01636.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/22900968/pubmed" id="22900968" target="_blank">22900968</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14713922">
<a name="14713922"></a>Manfredi M, Severino M, Testi S, et al. Detection of specific IgE to quinolones. <i>J Allergy Clin Immunol</i>. 2004;113(1):155‐160. doi:10.1016/j.jaci.2003.09.035<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/14713922/pubmed" id="14713922" target="_blank">14713922</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15929954">
<a name="15929954"></a>Martinez FJ, Grossman RF, Zadeikis N, et al. Patient stratification in the management of acute bacterial exacerbation of chronic bronchitis: the role of levofloxacin 750 mg.<i> Eur Respir J.</i> 2005;25(6):1001-1010. doi: 10.1183/09031936.05.00106404.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/15929954/pubmed" id="15929954" target="_blank">15929954</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30484869">
<a name="30484869"></a>Matsumoto T, Horino T, Inotani S, Ichii O, Terada Y. Drug reaction with eosinophilia and systemic symptoms/drug-induced hypersensitivity syndrome (DRESS/DIHS) caused by levofloxacin in a patient with systemic scleroderma, rheumatoid arthritis, and Sjogren syndrome. <i>Contact Dermatitis</i>. 2019;80(4):253‐254. doi:10.1111/cod.13188<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/30484869/pubmed" id="30484869" target="_blank">30484869</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25450476">
<a name="25450476"></a>Mattappalil A, Mergenhagen KA. Neurotoxicity with antimicrobials in the elderly: a review. <i>Clin Ther</i>. 2014;36(11):1489‐1511.e4. doi:10.1016/j.clinthera.2014.09.020<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/25450476/pubmed" id="25450476" target="_blank">25450476</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28085573">
<a name="28085573"></a>Mazuski JE, Tessier JM, May AK, et al. The Surgical Infection Society revised guidelines on the management of intra-abdominal infection. <i>Surg Infect (Larchmt).</i> 2017;18(1):1-76. doi: 10.1089/sur.2016.261.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/28085573/pubmed" id="28085573" target="_blank">28085573</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29462280">
<a name="29462280"></a>McDonald LC, Gerding DN, Johnson S, et al. Clinical practice guidelines for <i>Clostridium difficile</i> infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). <i>Clin Infect Dis</i>. 2018;66(7):e1‐e48. doi:10.1093/cid/cix1085<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/29462280/pubmed" id="29462280" target="_blank">29462280</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24457117">
<a name="24457117"></a>Meaney-Delman D, Zotti ME, Creanga AA, et al; Workgroup on Anthrax in Pregnant and Postpartum Women. Special considerations for prophylaxis for and treatment of anthrax in pregnant and postpartum women. <i>Emerg Infect Dis</i>. 2014;20(2):e130611. doi: 10.3201/eid2002.130611<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/24457117/pubmed" id="24457117" target="_blank">24457117</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30809871">
<a name="30809871"></a>Meng L, Huang J, Jia Y, Huang H, Qiu F, Sun S. Assessing fluoroquinolone-associated aortic aneurysm and dissection: data mining of the public version of the FDA adverse event reporting system. <i>Int J Clin Pract</i>. 2019;73(5):e13331. doi:10.1111/ijcp.13331<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/30809871/pubmed" id="30809871" target="_blank">30809871</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31573350">
<a name="31573350"></a>Metlay JP, Waterer GW, Long AC, et al. Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America. <i>Am J Resp Crit Care Med</i>. 2019;200(7):e45-e67. doi:10.1164/rccm.201908-1581ST.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/31573350/pubmed" id="31573350" target="_blank">31573350</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Meyrier.2022a">
<a name="Meyrier.2022a"></a>Meyrier A, Fekete T. Acute bacterial prostatitis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed June 22, 2022a.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Meyrier.2021">
<a name="Meyrier.2021"></a>Meyrier A, Fekete T. Chronic bacterial prostatitis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 23, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32459437">
<a name="32459437"></a>Miele K, Bamrah Morris S, Tepper NK. Tuberculosis in pregnancy. <i>Obstet Gynecol</i>. 2020;135(6):1444-1453. doi: 10.1097/AOG.0000000000003890<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/32459437/pubmed" id="32459437" target="_blank">32459437</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Mint-Levofloxacin [product monograph]. Mississauga, Ontario, Canada: Mint Pharmaceuticals Inc; September 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16185173">
<a name="16185173"></a>Mohr JF, McKinnon PS, Peymann PJ, Kenton I, Septimus E, Okhuysen PC. A retrospective, comparative evaluation of dysglycemias in hospitalized patients receiving gatifloxacin, levofloxacin, ciprofloxacin, or ceftriaxone. <i>Pharmacotherapy</i>. 2005;25(10):1303-1309. doi: 10.1592/phco.2005.25.10.1303.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/16185173/pubmed" id="16185173" target="_blank">16185173</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31034074">
<a name="31034074"></a>Morales D, Pacurariu A, Slattery J, Pinheiro L, McGettigan P, Kurz X. Association between peripheral neuropathy and exposure to oral fluoroquinolone or amoxicillin-clavulanate therapy. <i>JAMA Neurol</i>. 2019;76(7):827‐833. doi:10.1001/jamaneurol.2019.0887<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/31034074/pubmed" id="31034074" target="_blank">31034074</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34183510">
<a name="34183510"></a>Mora-López L, Ruiz-Edo N, Estrada-Ferrer O, et al; DINAMO-study Group. Efficacy and safety of nonantibiotic outpatient treatment in mild acute diverticulitis (DINAMO-study): a multicentre, randomised, open-label, noninferiority trial. <i>Ann Surg</i>. 2021;274(5):e435-e442. doi:10.1097/SLA.0000000000005031<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/34183510/pubmed" id="34183510" target="_blank">34183510</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2224281">
<a name="2224281"></a>Mumford CJ, Ginsberg L. Ciprofloxacin and myasthenia gravis. <i>BMJ</i>. 1990;301(6755):818. doi:10.1136/bmj.301.6755.818-a<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/2224281/pubmed" id="2224281" target="_blank">2224281</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31890418">
<a name="31890418"></a>Muradian M, Khan S. Levofloxacin-induced psychosis in a young healthy patient. <i>Cureus</i>. 2019;11(11):e6217. doi:10.7759/cureus.6217<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/31890418/pubmed" id="31890418" target="_blank">31890418</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27516382">
<a name="27516382"></a>Nahid P, Dorman SE, Alipanah N, et al. Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America clinical practice guidelines: treatment of drug-susceptible tuberculosis. <i>Clin Infect Dis.</i> 2016;63(7):e147-e195. doi:10.1093/cid/ciw376<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/27516382/pubmed" id="27516382" target="_blank">27516382</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31729908">
<a name="31729908"></a>Nahid P, Mase SR, Migliori GB, et al. Treatment of drug-resistant tuberculosis. An official ATS/CDC/ERS/IDSA clinical practice guideline. <i>Am J Respir Crit Care Med</i>. 2019;200(10):e93-e142. doi:10.1164/rccm.201909-1874ST<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/31729908/pubmed" id="31729908" target="_blank">31729908</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34264565">
<a name="34264565"></a>Nelson CA, Meaney-Delman D, Fleck-Derderian S, Cooley KM, Yu PA, Mead PS; contributors. Antimicrobial treatment and prophylaxis of plague: recommendations for naturally acquired infections and bioterrorism response. <i>MMWR Recomm Rep</i>. 2021;70(3):1-27. doi:10.15585/mmwr.rr7003a1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/34264565/pubmed" id="34264565" target="_blank">34264565</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22210007">
<a name="22210007"></a>Nicolau DP, Sutherland C, Winget D, Baughman RP. Bronchopulmonary pharmacokinetic and pharmacodynamic profiles of levofloxacin 750 mg once daily in adults undergoing treatment for acute exacerbation of chronic bronchitis.<i> Pulm Pharmacol Ther.</i> 2012;25(1):94-98. doi:10.1016/j.pupt.2011.12.007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/22210007/pubmed" id="22210007" target="_blank">22210007</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15714408">
<a name="15714408"></a>Nicolle LN, Bradley S, Colgan R et al, “Infectious Disease Society of America Guidelines for the Diagnosis and Treatment of Asymptomatic Bacteriuria in Adults,” <i>Clinical Infectious Diseases</i>, 2005, 40:643-54.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/15714408/pubmed" id="15714408" target="_blank">15714408</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18449063">
<a name="18449063"></a>Noel GJ, Blumer JL, Pichichero ME, et al. A randomized comparative study of levofloxacin versus amoxicillin/clavulanate for treatment of infants and young children with recurrent or persistent acute otitis media. <i>Pediatr Infect Dis J</i>. 2008;27(6):483-489. doi:10.1097/INF.0b013e318168d2cb<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/18449063/pubmed" id="18449063" target="_blank">18449063</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17901792">
<a name="17901792"></a>Noel GJ, Bradley JS, Kauffman RE, et al. Comparative safety profile of levofloxacin in 2523 children with a focus on four specific musculoskeletal disorders. <i>Pediatr Infect Dis J</i>. 2007;26(10):879-891. doi:10.1097/INF.0b013e3180cbd382<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/17901792/pubmed" id="17901792" target="_blank">17901792</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12709719">
<a name="12709719"></a>Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R. Effects of three fluoroquinolones on QT interval in healthy adults after single doses. <i>Clin Pharmacol Ther</i>. 2003;73(4):292‐303. doi:10.1016/s0009-9236(03)00009-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/12709719/pubmed" id="12709719" target="_blank">12709719</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31427300">
<a name="31427300"></a>Nys C, Cherabuddi K, Venugopalan V, Klinker KP. Clinical and microbiologic outcomes in patients with monomicrobial Stenotrophomonas maltophilia infections. <i>Antimicrob Agents Chemother.</i> 2019;63(11):e00788-19. doi:10.1128/AAC.00788-19<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/31427300/pubmed" id="31427300" target="_blank">31427300</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12841809">
<a name="12841809"></a>Oh YR, Carr-Lopez SM, Probasco JM, Crawley PG. Levofloxacin-induced autoimmune hemolytic anemia. <i>Ann Pharmacother</i>. 2003;37(7-8):1010‐1013. doi:10.1345/aph.1C525<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/12841809/pubmed" id="12841809" target="_blank">12841809</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10692119">
<a name="10692119"></a>Ohshima A, Seo N, Takigawa M, Tokura Y. Formation of antigenic quinolone photoadducts on Langerhans cells initiates photoallergy to systemically administered quinolone in mice. <i>J Invest Dermatol</i>. 2000;114(3):569‐575. doi:10.1046/j.1523-1747.2000.00918.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/10692119/pubmed" id="10692119" target="_blank">10692119</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21356330">
<a name="21356330"></a>Orman ES, Conjeevaram HS, Vuppalanchi R, et al. Clinical and histopathologic features of fluoroquinolone-induced liver injury. <i>Clin Gastroenterol Hepatol</i>. 2011;9(6):517‐523.e3. doi:10.1016/j.cgh.2011.02.019<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/21356330/pubmed" id="21356330" target="_blank">21356330</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23223583">
<a name="23223583"></a>Osmon DR, Berbari EF, Berendt AR, et al; Infectious Diseases Society of America. Diagnosis and management of prosthetic joint infection: clinical practice guidelines by the Infectious Diseases Society of America. <i>Clin Infect Dis</i>. 2013;56(1):e1-e25. doi: 10.1093/cid/cis803.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/23223583/pubmed" id="23223583" target="_blank">23223583</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Osmon.2019">
<a name="Osmon.2019"></a>Osmon DR, Tanje AJ. Osteomyelitis in adults: treatment. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed August 29, 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30401472">
<a name="30401472"></a>Ouni B, Fathallah N, Slim R, Brahim A, Ben Salem C. Anaphylactic shock secondary to oral ofloxacin administration with cross-reactivity to levofloxacin and ciprofloxacin. <i>Therapie</i>. 2018;73(6):555‐556. doi:10.1016/j.therap.2018.05.001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/30401472/pubmed" id="30401472" target="_blank">30401472</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20598025">
<a name="20598025"></a>Ozyüncü O, Beksac MS, Nemutlu E, Katlan D, Kir S. Maternal blood and amniotic fluid levels of moxifloxacin, levofloxacin and cefixime. <i>J Obstet Gynaecol Res</i>. 2010a;36(3):484-487.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/20598025/pubmed" id="20598025" target="_blank">20598025</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20418070">
<a name="20418070"></a>Ozyüncü O, Nemutlu E, Katlan D, Kir S, Beksac MS. Maternal and fetal blood levels of moxifloxacin, levofloxacin, cefepime and cefoperazone. <i>Int J Antimicrob Agents</i>. 2010b;36(2):175-178.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/20418070/pubmed" id="20418070" target="_blank">20418070</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24841264">
<a name="24841264"></a>Padberg S, Wacker E, Meister R, et al. Observational cohort study of pregnancy outcome after first-trimester exposure to fluoroquinolones. <i>Antimicrob Agents Chemother</i>. 2014;58(8):4392-4398.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/24841264/pubmed" id="24841264" target="_blank">24841264</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24989061">
<a name="24989061"></a>Pai MP, Cojutti P, Pea F. Levofloxacin dosing regimen in severely morbidly obese patients (BMI ≥40 kg/m(2)) should be guided by creatinine clearance estimates based on ideal body weight and optimized by therapeutic drug monitoring.<i> Clin Pharmacokinet</i>. 2014;53(8):753-762. doi:10.1007/s40262-014-0154-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/24989061/pubmed" id="24989061" target="_blank">24989061</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27553825">
<a name="27553825"></a>Pan L, Wang Z, Xu Y. Levofloxacin-induced transient musculospiral paralysis. <i>Am J Emerg Med</i>. 2017;35(2):375.e1-e375.e2.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/27553825/pubmed" id="27553825" target="_blank">27553825</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29519881">
<a name="29519881"></a>Pasternak B, Inghammar M, Svanström H. Fluoroquinolone use and risk of aortic aneurysm and dissection: nationwide cohort study. <i>BMJ</i>. 2018;360:k678. doi:10.1136/bmj.k678<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/29519881/pubmed" id="29519881" target="_blank">29519881</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26865283">
<a name="26865283"></a>Patel K, Goldman JL. Safety concerns surrounding quinolone use in children. <i>J Clin Pharmacol</i>. 2016;56(9):1060-1075. doi:10.1002/jcph.715<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/26865283/pubmed" id="26865283" target="_blank">26865283</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Patel.1">
<a name="Patel.1"></a>Patel ZM, Hwang PH. Uncomplicated acute sinusitis and rhinosinusitis in adults: treatment. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed June 23, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18027987">
<a name="18027987"></a>Pea F, Viale P, Pavan F, Furlanut M. Pharmacokinetic considerations for antimicrobial therapy in patients receiving renal replacement therapy. <i>Clin Pharmacokinet</i>. 2007;46(12):997-1038.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/18027987/pubmed" id="18027987" target="_blank">18027987</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Pemberton.1">
<a name="Pemberton.1"></a>Pemberton JH. Acute colonic diverticulitis: Medical management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed April 14, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29928218">
<a name="29928218"></a>Popescu C. Severe acute axonal neuropathy induced by ciprofloxacin: a case report. <i>Case Rep NeurolPorta L, Lee MG, Hsu WT, Hsu TC, Tsai TY, Lee CC. Fluoroquinolone use and serious arrhythmias: A nationwide case-crossover study. </i><i>Resuscitation</i><i>. 2019;139:262‐268. doi:10.1016/j.resuscitation.2019.04.030</i>. 2018;10(2):124‐129. doi:10.1159/000489303<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/29928218/pubmed" id="29928218" target="_blank">29928218</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31029713">
<a name="31029713"></a>Porta L, Lee MG, Hsu WT, Hsu TC, Tsai TY, Lee CC. Fluoroquinolone use and serious arrhythmias: A nationwide case-crossover study. <i>Resuscitation</i>. 2019;139:262‐268. doi:10.1016/j.resuscitation.2019.04.030<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/31029713/pubmed" id="31029713" target="_blank">31029713</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9440662">
<a name="9440662"></a>Preston SL, Drusano GL, Berman AL, et al. Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials. <i>JAMA</i>. 1998;279(2):125-129. doi:10.1001/jama.279.2.125<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/9440662/pubmed" id="9440662" target="_blank">9440662</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12552523">
<a name="12552523"></a>Ramalakshmi S, Bastacky S, Johnson JP. Levofloxacin-induced granulomatous interstitial nephritis. <i>Am J Kidney Dis</i>. 2003;41(2):E7. doi:10.1053/ajkd.2003.50064<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/12552523/pubmed" id="12552523" target="_blank">12552523</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32561442">
<a name="32561442"></a>Ramirez JA, Musher DM, Evans SE, et al. Treatment of community-acquired pneumonia in immunocompromised adults: a consensus statement regarding initial strategies. <i>Chest</i>. 2020;158(5):1896-1911. doi:10.1016/j.chest.2020.05.598<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/32561442/pubmed" id="32561442" target="_blank">32561442</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26666946">
<a name="26666946"></a>Roberts JA, Cotta MO, Cojutti P, Lugano M, Della Rocca G, Pea F. Does critical illness change levofloxacin pharmacokinetics?<i> Antimicrob Agents Chemother.</i> 2016;60(3):1459-1463. doi:10.1128/AAC.02610-15<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/26666946/pubmed" id="26666946" target="_blank">26666946</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14999113">
<a name="14999113"></a>Roden DM. Drug-induced prolongation of the QT interval. <i>N Engl J Med</i>. 2004;350(10):1013‐1022. doi:10.1056/NEJMra032426<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/14999113/pubmed" id="14999113" target="_blank">14999113</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25832968">
<a name="25832968"></a>Rosenfeld RM, Piccirillo JF, Chandrasekhar SS, et al. Clinical practice guideline (update): adult sinusitis. <i>Otolaryngol Head Neck Surg. </i>2015;152(2)(suppl):S1-S39. doi: 10.1177/0194599815572097.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/25832968/pubmed" id="25832968" target="_blank">25832968</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21164064">
<a name="21164064"></a>Salloum R, Liu CY, Weise AM. Possible case of levofloxacin-induced thrombocytopenia. <i>Am J Health Syst Pharm</i>. 2011;68(1):43‐46. doi:10.2146/ajhp090564<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/21164064/pubmed" id="21164064" target="_blank">21164064</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15910010">
<a name="15910010"></a>Sánchez Navarro A, Colino Gandarillas CI, Alvarez Lerma F, Menacho YA, Domínguez-Gil A. Pharmacokinetics and pharmacodynamics of levofloxacin in intensive care patients. <i>Clin Pharmacokinet</i>. 2005;44(6):627-635. doi:10.2165/00003088-200544060-00004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/15910010/pubmed" id="15910010" target="_blank">15910010</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25992746">
<a name="25992746"></a>Sawyer RG, Claridge JA, Nathens AB, et al; STOP-IT Trial Investigators. Trial of short-course antimicrobial therapy for intraabdominal infection. <i>N Engl J Med</i>. 2015;372(21):1996-2005. doi:10.1056/NEJMoa1411162<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/25992746/pubmed" id="25992746" target="_blank">25992746</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1461695">
<a name="1461695"></a>Schaad UB, “Role of the New Quinolones in Pediatric Practice,” <i>Pediatr Infect Dis J</i>, 1992, 11(12):1043-6.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/1461695/pubmed" id="1461695" target="_blank">1461695</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8320021">
<a name="8320021"></a>Scheife RT, Cramer WR, Decker EL. Photosensitizing potential of ofloxacin. <i>Int J Dermatol</i>. 1993;32(6):413‐416. doi:10.1111/j.1365-4362.1993.tb02810.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/8320021/pubmed" id="8320021" target="_blank">8320021</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29523775">
<a name="29523775"></a>Schloss M, Becak D, Tosto ST, Velayati A. A case of levoﬂoxacin-induced hepatotoxicity. <i>Am J Case Rep</i>. 2018;19:272‐276. doi:10.12659/ajcr.907440<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/29523775/pubmed" id="29523775" target="_blank">29523775</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16393267">
<a name="16393267"></a>Schmid DA, Depta JP, Pichler WJ. T cell-mediated hypersensitivity to quinolones: mechanisms and cross-reactivity. <i>Clin Exp Allergy</i>. 2006;36(1):59‐69. doi:10.1111/j.1365-2222.2006.02402.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/16393267/pubmed" id="16393267" target="_blank">16393267</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15890441">
<a name="15890441"></a>Sendzik J, Shakibaei M, Schäfer-Korting M, Stahlmann R. Fluoroquinolones cause changes in extracellular matrix, signalling proteins, metalloproteinases and caspase-3 in cultured human tendon cells. <i>Toxicology</i>. 2005;212(1):24‐36. doi:10.1016/j.tox.2005.04.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/15890441/pubmed" id="15890441" target="_blank">15890441</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20034766">
<a name="20034766"></a>Sendzik J, Shakibaei M, Schäfer-Korting M, Lode H, Stahlmann R. Synergistic effects of dexamethasone and quinolones on human-derived tendon cells. <i>Int J Antimicrob Agents</i>. 2010;35(4):366‐374. doi:10.1016/j.ijantimicag.2009.10.009<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/20034766/pubmed" id="20034766" target="_blank">20034766</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18230552">
<a name="18230552"></a>Senneville E, Poissy J, Legout L, et al. Safety of prolonged high-dose levofloxacin therapy for bone infections. <i>J Chemother</i>. 2007;19(6):688-693. doi: 10.1179/joc.2007.19.6.688.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/18230552/pubmed" id="18230552" target="_blank">18230552</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Sethi.1">
<a name="Sethi.1"></a>Sethi S, Murphy TF. Management of infection in exacerbations of chronic obstructive pulmonary disease. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="https://www.uptodate.com" target="_blank">https://www.uptodate.com</a>. Accessed May 16, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33524402">
<a name="33524402"></a>Shah SC, Iyer PG, Moss SF. AGA clinical practice update on the management of refractory Helicobacter pylori infection: expert review. <i>Gastroenterology</i>. 2021;160(5):1831-1841. doi:10.1053/j.gastro.2020.11.059<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/33524402/pubmed" id="33524402" target="_blank">33524402</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28719679">
<a name="28719679"></a>Shah SD, Cifu AS. Management of acute diverticulitis. <i>JAMA</i>. 2017;318(3):291-292. doi:10.1001/jama.2017.6373<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/28719679/pubmed" id="28719679" target="_blank">28719679</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29053792">
<a name="29053792"></a>Shane AL, Mody RK, Crump JA, et al. 2017 Infectious Diseases Society of America clinical practice guidelines for the diagnosis and management of infectious diarrhea. <i>Clin Infect Dis</i>. 2017;65(12):e45-e80. doi:10.1093/cid/cix669<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/29053792/pubmed" id="29053792" target="_blank">29053792</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19188870">
<a name="19188870"></a>Shehab N, Lewis CL, Streetman DD, Donn SM. Exposure to the pharmaceutical excipients benzyl alcohol and propylene glycol among critically ill neonates. <i>Pediatr Crit Care Med</i>. 2009;10(2):256-259.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/19188870/pubmed" id="19188870" target="_blank">19188870</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25024854">
<a name="25024854"></a>Sheikh-Taha M, Frenn P. Autoimmune hemolytic anemia induced by levofloxacin. <i>Case Rep Infect Dis</i>. 2014;2014:201015. doi:10.1155/2014/201015<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/25024854/pubmed" id="25024854" target="_blank">25024854</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28403679">
<a name="28403679"></a>Shih AW, Lam AS, Warkentin TE. Levofloxacin-induced acute immune-mediated thrombocytopenia of rapid-onset. <i>J Pharm Pract</i>. 2018;31(2):234‐237. doi:10.1177/0897190017702306<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/28403679/pubmed" id="28403679" target="_blank">28403679</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28791716">
<a name="28791716"></a>Sim DW, Yu JE, Jeong J, Koh YI. Ciprofloxacin-induced immune-mediated thrombocytopenia: No cross-reactivity with gemifloxacin. <i>J Clin Pharm Ther</i>. 2018;43(1):134‐136. doi:10.1111/jcpt.12596<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/28791716/pubmed" id="28791716" target="_blank">28791716</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28739200">
<a name="28739200"></a>Singh S, Nautiyal A. Aortic dissection and aortic aneurysms associated with fluoroquinolones: a systematic review and meta-analysis. <i>Am J Med</i>. 2017;130(12):1449‐1457.e9. doi:10.1016/j.amjmed.2017.06.029<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/28739200/pubmed" id="28739200" target="_blank">28739200</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11130225">
<a name="11130225"></a>Smythe MA, Cappelletty DM. Anaphylactoid reaction to levofloxacin. <i>Pharmacotherapy</i>. 2000;20(12):1520‐1523. doi:10.1592/phco.20.19.1520.34868<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/11130225/pubmed" id="11130225" target="_blank">11130225</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30246872">
<a name="30246872"></a>Sobrino-García M, Gómez-Cardeñosa A, Moreno-Rodilla E, Muñoz-Bellido FJ, Lázaro-Sastre M, Dávila I. A case report of fixed drug eruption caused by several drugs because of cross-reactivity and co-sensitization. <i>Contact Dermatitis</i>. 2019;80(1):56‐57. doi:10.1111/cod.13115<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/30246872/pubmed" id="30246872" target="_blank">30246872</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20034345">
<a name="20034345"></a>Solomkin JS, Mazuski JE, Bradley JS, et al. Diagnosis and management of complicated intra-abdominal infections in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America [published correction appears in <i>Clin Infect Dis. </i>2010;50(12):1695]. <i>Clin Infect Dis.</i> 2010;50(2):133-164.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/20034345/pubmed" id="20034345" target="_blank">20034345</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12900817">
<a name="12900817"></a>Sowinski KM, Lucksiri A, Kays MB, Scott MK, Mueller BA, Hamburger RJ. Levofloxacin pharmacokinetics in ESRD and removal by the cellulose acetate high performance-210 hemodialyzer. <i>Am J Kidney Dis</i>. 2003;42(2):342-349.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/12900817/pubmed" id="12900817" target="_blank">12900817</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9593160">
<a name="9593160"></a>Spangler SK, Lin G, Jacobs MR, Appelbaum PC. Postantibiotic effect and postantibiotic sub-MIC effect of levofloxacin compared to those of ofloxacin, ciprofloxacin, erythromycin, azithromycin, and clarithromycin against 20 pneumococci. <i>Antimicrob Agents Chemother.</i> 1998;42(5):1253-1255. doi:10.1128/AAC.42.5.1253<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/9593160/pubmed" id="9593160" target="_blank">9593160</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Spelman.1">
<a name="Spelman.1"></a>Spelman D, Baddour LM. Acute cellulitis and erysipelas in adults: Treatment. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed August 4, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26766291">
<a name="26766291"></a>Srinivas NR. Influence of morbid obesity on the clinical pharmacokinetics of various anti-infective drugs: reappraisal using recent case studies-issues, dosing implications, and considerations. <i>Am J Ther</i>. 2018;25(2):e224-e246. doi:10.1097/MJT.0000000000000401<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/26766291/pubmed" id="26766291" target="_blank">26766291</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28063266">
<a name="28063266"></a>Stefano GB, Samuel J, Kream RM. Antibiotics may trigger mitochondrial dysfunction inducing psychiatric disorders. <i>Med Sci Monit</i>. 2017;23:101‐106. doi:10.12659/msm.899478<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/28063266/pubmed" id="28063266" target="_blank">28063266</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24947530">
<a name="24947530"></a>Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America [published online ahead of print June 18, 2014]. <i>Clin Infect Dis</i>. 2014;59(2):e10-e52. doi: 10.1093/cid/ciu296.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/24947530/pubmed" id="24947530" target="_blank">24947530</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26453777">
<a name="26453777"></a>Stollman N, Smalley W, Hirano I; AGA Institute Clinical Guidelines Committee. American Gastroenterological Association Institute guideline on the management of acute diverticulitis. <i>Gastroenterology</i>. 2015;149(7):1944-1949. doi:10.1053/j.gastro.2015.10.003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/26453777/pubmed" id="26453777" target="_blank">26453777</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Stout.1">
<a name="Stout.1"></a>Stout J. Clinical manifestations, diagnosis, and treatment of plague (Yersinia pestis infection). Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 17, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26400582">
<a name="26400582"></a>Sutter R, Rüegg S, Tschudin-Sutter S. Seizures as adverse events of antibiotic drugs: A systematic review. <i>Neurology</i>. 2015;85(15):1332‐1341. doi:10.1212/WNL.0000000000002023<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/26400582/pubmed" id="26400582" target="_blank">26400582</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34864936">
<a name="34864936"></a>Tamma PD, Aitken SL, Bonomo RA, Mathers AJ, van Duin D, Clancy CJ. Infectious Diseases Society of America guidance on the treatment of AmpC β-Lactamase-producing Enterobacterales, Carbapenem-resistant Acinetobacter baumannii, and Stenotrophomonas maltophilia infections. <i>Clin Infect Dis</i>. 2022;74(12):2089-2114. doi:10.1093/cid/ciab1013<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/34864936/pubmed" id="34864936" target="_blank">34864936</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29702230">
<a name="29702230"></a>Tandan M, Cormican M, Vellinga A. Adverse events of fluoroquinolones vs. other antimicrobials prescribed in primary care: a systematic review and meta-analysis of randomized controlled trials. <i>Int J Antimicrob Agents</i>. 2018;52(5):529‐540. doi:10.1016/j.ijantimicag.2018.04.014<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/29702230/pubmed" id="29702230" target="_blank">29702230</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29461916">
<a name="29461916"></a>Taplitz RA, Kennedy EB, Bow EJ, et al. Outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology and Infectious Diseases Society of America Clinical Practice Guideline Update. <i>J Clin Oncol</i>. 2018;36(14):1443-1453. doi:10.1200/JCO.2017.77.6211.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/29461916/pubmed" id="29461916" target="_blank">29461916</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31341415">
<a name="31341415"></a>Teng C, Walter EA, Gaspar DKS, Obodozie-Ofoegbu OO, Frei CR. Torsades de pointes and QT prolongation associations with antibiotics: a pharmacovigilance study of the FDA adverse event reporting system. <i>Int J Med Sci</i>. 2019;16(7):1018‐1022. doi:10.7150/ijms.34141<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/31341415/pubmed" id="31341415" target="_blank">31341415</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24550337">
<a name="24550337"></a>Thee S, Garcia-Prats AJ, McIlleron HM, et al. Pharmacokinetics of ofloxacin and levofloxacin for prevention and treatment of multidrug-resistant tuberculosis in children. <i>Antimicrob Agents Chemother.</i> 2014;58(5):2948-2951. doi:10.1128/AAC.02755-13<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/24550337/pubmed" id="24550337" target="_blank">24550337</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32929996">
<a name="32929996"></a>Tisdale JE, Chung MK, Campbell KB, et al; American Heart Association Clinical Pharmacology Committee of the Council on Clinical Cardiology and Council on Cardiovascular and Stroke Nursing. Drug-induced arrhythmias: A scientific statement from the American Heart Association. <i>Circulation</i>. 2020;142(15):e214-e233. doi: 10.1161/CIR.0000000000000905.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/32929996/pubmed" id="32929996" target="_blank">32929996</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23716032">
<a name="23716032"></a>Tisdale JE, Jaynes HA, Kingery JR, et al. Development and validation of a risk score to predict QT interval prolongation in hospitalized patients. <i>Circ Cardiovasc Qual Outcomes</i>. 2013;6(4):479‐487. doi:10.1161/CIRCOUTCOMES.113.000152<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/23716032/pubmed" id="23716032" target="_blank">23716032</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22971191">
<a name="22971191"></a>Tolland JP, Murphy BP, Boyle J, Hall V, McKenna KE, Elborn JS. Ciprofloxacin-induced phototoxicity in an adult cystic fibrosis population. <i>Photodermatol Photoimmunol Photomed</i>. 2012;28(5):258‐260. doi:10.1111/j.1600-0781.2012.00676.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/22971191/pubmed" id="22971191" target="_blank">22971191</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19747629">
<a name="19747629"></a>Tomblyn M, Chiller T, Einsele H, et al; Center for International Blood and Marrow Research; National Marrow Donor program; European Blood and Marrow Transplant Group; et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective [published correction appears in <i>Biol Blood Marrow Transplant</i>. 2010;16(2):294]. <i>Biol Blood Marrow Transplant</i>. 2009;15(10):1143-1238. doi: 10.1016/j.bbmt.2009.06.019.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/19747629/pubmed" id="19747629" target="_blank">19747629</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21585220">
<a name="21585220"></a>Tomé AM, Filipe A. Quinolones: review of psychiatric and neurological adverse reactions. <i>Drug Saf</i>. 2011;34(6):465‐488. doi:10.2165/11587280-000000000-00000<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/21585220/pubmed" id="21585220" target="_blank">21585220</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16163635">
<a name="16163635"></a>Trotman RL, Williamson JC, Shoemaker DM, Salzer WL. Antibiotic dosing in critically ill adult patients receiving continuous renal replacement therapy. <i>Clin Infect Dis.</i> 2005;41(8):1159-1166.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/16163635/pubmed" id="16163635" target="_blank">16163635</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22035890">
<a name="22035890"></a>Tsai WC, Yang YM. Fluoroquinolone-associated tendinopathy. <i>Chang Gung Med J</i>. 2011;34(5):461‐467.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/22035890/pubmed" id="22035890" target="_blank">22035890</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16472283">
<a name="16472283"></a>Tsikouris JP, Peeters MJ, Cox CD, Meyerrose GE, Seifert CF. Effects of three fluoroquinolones on QT analysis after standard treatment courses. <i>Ann Noninvasive Electrocardiol</i>. 2006;11(1):52‐56. doi:10.1111/j.1542-474X.2006.00082.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/16472283/pubmed" id="16472283" target="_blank">16472283</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21715074">
<a name="21715074"></a>Tsuruoka S, Yokota N, Hayasaka T, Saito T, Yamagata K. Pharmacokinetics of multiple-dose levofloxacin in hemodialysis patients. <i>Am J Kidney Dis</i>. 2011;58(3):498-499. doi:10.1053/j.ajkd.2011.05.014<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/21715074/pubmed" id="21715074" target="_blank">21715074</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20000886">
<a name="20000886"></a>Udy AA, Roberts JA, Boots RJ, Paterson DL, Lipman J. Augmented renal clearance: implications for antibacterial dosing in the critically ill. <i>Clin Pharmacokinet</i>. 2010;49(1):1-16. doi:10.2165/11318140-000000000-00000<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/20000886/pubmed" id="20000886" target="_blank">20000886</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-FDA..2016">
<a name="FDA..2016"></a>US Food and Drug Administration (FDA). FDA Drug Safety Communication. FDA advises restricting fluoroquinolone antibiotic use for certain uncomplicated infections; warns about disabling side effects that can occur together. <a href="http://www.fda.gov/Drugs/DrugSafety/ucm511530.htm" target="_blank">http://www.fda.gov/Drugs/DrugSafety/ucm511530.htm</a>. Published May 12, 2016. Accessed November 18, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.2020">
<a name="HHS.2020"></a>US Department of Health and Human Services (HHS) Panel on Opportunistic Infections in Adults and Adolescents with HIV. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV. <a href="https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/Adult_OI.pdf" target="_blank">https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/Adult_OI.pdf</a>. Updated October 2019. Accessed June 17, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.2013">
<a name="HHS.2013"></a>US Department of Health and Human Services (HHS) Panel on Opportunistic Infections in HIV-Exposed and HIV-Infected Children. Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Exposed and HIV-Infected Children. Department of Health and Human Services. November 2013. Available at <a href="https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/OI_Guidelines_Pediatrics.pdf" target="_blank">https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/OI_Guidelines_Pediatrics.pdf</a>.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.2016">
<a name="HHS.2016"></a>US Department of Health and Human Services (HHS) Panel on Opportunistic Infections in HIV-Exposed and HIV-Infected Children. Guidelines for the prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children. <a href="https://aidsinfo.nih.gov/contentfiles/lvguidelines/oi_guidelines_pediatrics.pdf" target="_blank">https://aidsinfo.nih.gov/contentfiles/lvguidelines/oi_guidelines_pediatrics.pdf</a>. Accessed December 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27634312">
<a name="27634312"></a>Uzun R, Yalcin AD, Celik B, Bulut T, Yalcin AN. Levofloxacin induced toxic epidermal necrolysis: successful therapy with omalizumab (anti-IgE) and pulse prednisolone. <i>Am J Case Rep</i>. 2016;17:666‐671. doi:10.12659/ajcr.899823<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/27634312/pubmed" id="27634312" target="_blank">27634312</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12039823">
<a name="12039823"></a>van der Linden PD, Sturkenboom MC, Herings RM, Leufkens HG, Stricker BH. Fluoroquinolones and risk of Achilles tendon disorders: case-control study. <i>BMJ</i>. 2002;324(7349):1306‐1307. doi:10.1136/bmj.324.7349.1306<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/12039823/pubmed" id="12039823" target="_blank">12039823</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32073652">
<a name="32073652"></a>van Dijk ST, Chabok A, Dijkgraaf MG, Boermeester MA, Smedh K. Observational versus antibiotic treatment for uncomplicated diverticulitis: an individual-patient data meta-analysis. <i>Br J Surg</i>. 2020;107(8):1062-1069. doi:10.1002/bjs.11465<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/32073652/pubmed" id="32073652" target="_blank">32073652</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27216385">
<a name="27216385"></a>Vardakas KZ, Trigkidis KK, Boukouvala E, Falagas ME. <i>Clostridium difficile</i> infection following systemic antibiotic administration in randomised controlled trials: a systematic review and meta-analysis. <i>Int J Antimicrob Agents</i>. 2016;48(1):1‐10. doi:10.1016/j.ijantimicag.2016.03.008<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/27216385/pubmed" id="27216385" target="_blank">27216385</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Vollmer.1">
<a name="Vollmer.1"></a>Vollmer CM, Zakko SF, Afdhal NH. Treatment of acute calculous cholecystitis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed April 14, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22946871">
<a name="22946871"></a>Vossen MG, Thalhammer F. Effects of renal replacement therapy on antimicrobial therapy. <i>Curr Clin Pharmacol</i>. 2013;8(1):39-45.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/22946871/pubmed" id="22946871" target="_blank">22946871</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22851742">
<a name="22851742"></a>Warady BA, Bakkaloglu S, Newland J, et al, "Consensus Guidelines for the Prevention and Treatment of Catheter-Related Infections and Peritonitis in Pediatric Patients Receiving Peritoneal Dialysis: 2012 Update," <i>Perit Dial Int</i>, 2012, (32 Suppl 2):S32-86.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/22851742/pubmed" id="22851742" target="_blank">22851742</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29272341">
<a name="29272341"></a>Watson T, Hickok J, Fraker S, Korwek K, Poland RE, Septimus E. Evaluating the risk factors for hospital-onset <i>Clostridium difficile</i> infections in a large healthcare system. <i>Clin Infect Dis</i>. 2018;66(12):1957‐1959. doi:10.1093/cid/cix1112<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/29272341/pubmed" id="29272341" target="_blank">29272341</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Weintrob.1">
<a name="Weintrob.1"></a>Weintrob AC, Sexton DJ. Clinical manifestations, diagnosis, and management of diabetic infections of the lower extremities. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed November 24, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Wiesenfeld.1">
<a name="Wiesenfeld.1"></a>Wiesenfeld HC. Pelvic inflammatory disease: Treatment in adults and adolescents. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed July 20, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Wilson.1">
<a name="Wilson.1"></a>Wilson KH. Prevention of anthrax. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 21, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Wingard.1">
<a name="Wingard.1"></a>Wingard JR. Prophylaxis of infection during chemotherapy-induced neutropenia in high-risk adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed November 11, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26042815">
<a name="26042815"></a>Workowski KA, Bolan GA; Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2015. <i>MMWR Recomm Rep</i>. 2015;64(RR-03):1-137.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/26042815/pubmed" id="26042815" target="_blank">26042815</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34292926">
<a name="34292926"></a>Workowski KA, Bachmann LH, Chan PA, et al. Sexually transmitted infections treatment guidelines, 2021. <i>MMWR Recomm Rep</i>. 2021;70(4):1-187. doi:10.15585/mmwr.rr7004a1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/34292926/pubmed" id="34292926" target="_blank">34292926</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WHO.2002">
<a name="WHO.2002"></a>World Health Organization (WHO). Breastfeeding and maternal medication, recommendations for drugs in the eleventh WHO model list of essential drugs. 2002. Available at http://www.who.int/maternal_child_adolescent/documents/55732/en/
                  </div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WHO.2002">
<a name="WHO.2002"></a>World Health Organization (WHO). Guidelines for the management of symptomatic sexually transmitted infections. World Health Organization; 2021. https://www.who.int/publications/i/item/9789240024168
                  </div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WHO.2019">
<a name="WHO.2019"></a>World Health Organization (WHO). WHO consolidated guidelines on drug-resistant tuberculosis treatment<i>.</i> World Health Organization; 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WHO.2020">
<a name="WHO.2020"></a>World Health Organization (WHO). WHO consolidated guidelines on tuberculosis, module 4: treatment - drug-resistant tuberculosis treatment. World Health Organization; 2020. https://www.who.int/publications/i/item/9789240007048.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WHO.2005">
<a name="WHO.2005"></a>World Health Organization (WHO) Guidelines for the control of shigellosis, including epidemics due to Shigella dysenteriae type 1. 2005. https://apps.who.int/iris/bitstream/handle/10665/43252/924159330X.pdf;jsessionid=22043002F7FC0FF4035BE12F8B59E31E?sequence=1
                  </div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29319210">
<a name="29319210"></a>Yefet E, Schwartz N, Chazan B, Salim R, Romano S, Nachum Z. The safety of quinolones and fluoroquinolones in pregnancy: a meta-analysis. <i>BJOG</i>. 2018;125(9):1069-1076. doi: 10.1111/1471-0528.15119<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/29319210/pubmed" id="29319210" target="_blank">29319210</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31077091">
<a name="31077091"></a>Yu X, Jiang DS, Wang J, et al. Fluoroquinolone use and the risk of collagen-associated adverse events: a systematic review and meta-analysis. <i>Drug Saf</i>. 2019;42(9):1025‐1033. doi:10.1007/s40264-019-00828-z<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/31077091/pubmed" id="31077091" target="_blank">31077091</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29582196">
<a name="29582196"></a>Ziv A, Masarwa R, Perlman A, Ziv D, Matok I. Pregnancy outcomes following exposure to quinolone antibiotics - a systematic-review and meta-analysis. <i>Pharm Res</i>. 2018;35(5):109. doi: 10.1007/s11095-018-2383-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/levofloxacin-systemic-pediatric-drug-information/abstract-text/29582196/pubmed" id="29582196" target="_blank">29582196</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 16013 Version 627.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
